СПОСОБ ПОЛУЧЕНИЯ БИС-БЕНЗАЗОЛИЛОВЫХ СОЕДИНЕНИЙ

Изобретение относится к способу получения соединения формулы в которой Y обозначает -O-, -S- или -N(R2)-, причем R2 обозначает водородный атом, C1-C10алкил или аралкил; Z обозначает 2,5-фураниловый, 2,5-тиофениловый, 4,4'-стильбениловый или 1,2-этилениловый остаток, a R1обозначает атом водорода или галогена, C1-C10алкил, С1-С10алкокси, цианогруппу, СООМ или SO3М, причем М обозначает водородный атом или атом щелочного или щелочноземельного металла. Способ заключается в том, что проводят реакцию соединения формулы с дикарбоновой кислотой формулы или ее эфиром, причем Y, Z и R1 имеют значения, указанные выше, в N-метилпирролидоне или N,N-диметилацетамиде в присутствии кислотного катализатора и необязательно в присутствии вспомогательного растворителя, способного удалять из реакционной смеси воду. 10 з.п. ф-лы.

ПРОИЗВОДНЫЕ БЕНЗИМИДАЗОЛА, ИХ ТАУТОМЕРЫ ИЛИ ИХ СОЛИ И ЛЕКАРСТВЕННОЕ СРЕДСТВО С АНТАГОНИСТИЧЕСКИМ В ОТНОШЕНИИ АНГИОТЕНЗИНА II ДЕЙСТВИЕМ

Производные бензимидазола формулы I, где R1 - C1-3 - алкил, R2 - 5-, 6- или 7-членная алкилениминогруппа, в которой одна метиленовая группа заменена сульфонильной группой, незамещенная или замещенная в положении 1 алкилом бензимидазол - 2-ил или 4, 5, 6, 7-тетрагидробензимидазол - 2-ил, имидазо [1,2-a] пиридин-2-ил, 3-хлор-5, 6, 7, 8-тетрагидроимидазо [1,2-a] пиризин-2-ил; R3 - алкил, C3-5 - циклоалкил или алкоксил; R4 - замещенный в положении 1 и 2 Ra-CO-O-CH2-группой тетразолил, группа Rв-CO-O-(RcCH)-O-CO-RaO-CO- и RвO-CO-O(RcCH)-O-CO-, Ra и Rв- C1-6 - алкил, C5-7 - циклоалкил; Rс - водород или метил, их таутомеры или их соли. Соединения I расширяют ассортимент производных бензимидазола, обладающих антагонистическим в отношении ангиотензина II действием. 2 с.п. ф-лы, 1 табл.

ИНГРЕДИЕНТ ПРОЯВЛЯЮЩИХ КОМПОЗИЦИЙ

Изобретение касается применения бис-четвертичных солей бензимидазолия общей ф-лы где n = 1 или 2; B-H,CH3 B1-H,Cl R-CH3 или C2H5 Х - иод, перхлорат, тозилат, в качестве инградиента проявляющих композиций, используемых в галогеносеребряных фотоматериалах. В эом случае достигается повышение светочувствительности фотоматериала или снижение плотности вуали при химико-фотографической обработке (при проявлении) фотоматериалов с повышенной плотностью вуали. 2 табл.

НИТРООКСИПРОИЗВОДНЫЕ ЛОЗАРТАНА, ВАЛСАРТАНА, КАНДЕСАРТАНА, ТЕЛМИСАРТАНА, ЭПРОСАРТАНА И ОЛМЕСАРТАНА В КАЧЕСТВЕ БЛОКАТОРОВ РЕЦЕПТОРОВ АНГИОТЕНЗИНА II ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ

... 1. Соединения общей формулы (I) или их фармацевтически приемлемые соли или стереоизомерыгде s равно 1 или 2;R выбирают из следующих остатков блокаторов рецептора ангиотензина II формулы (II) или (III):гдеRпредставляетили -N, где -Nпредставляет собой способную к связыванию с Y группу, имеющую одно из следующих значений:-СОО-, -О-, -CONH-, -ОСО-, -ОСОО- илигде R' и R" одинаковые или разные и представляют собой Н или прямой или разветвленный C-Cалкил;Rвыбирают из группы, состоящей изгде m целое число, равное 0 или 1, и No как указано выше;где Nимеет значения, указанные для No или равно -СООН;при условии, что по крайней мере одна из групп Nравна -СОО- или -CONH-, то есть это группа, способная связываться с Y;Y представляет собой двухвалентный радикал, имеющий следующие значения:a)прямой или разветвленный C-Cалкилен, преимущественно С-С, необязательно замещенный одним или более заместителями, выбранными из группы, состоящей из: атомов галогена, гидрокси, -ONOили Т, где Тпредставляет -СО(O)(С-Салкил ...

ПРОИЗВОДНЫЕ БЕНЗИМИДАЗОЛА, СМЕСЬ ИХ ИЗОМЕРОВ ИЛИ ОТДЕЛЬНЫЕ ИЗОМЕРЫ И ИХ СОЛИ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С АНТАГОНИСТИЧЕСКОЙ В ОТНОШЕНИИ АНГИОТЕНЗИНА АКТИВНОСТЬЮ НА ИХ ОСНОВЕ

Предлагаются производные бензимидазола общей формулы I, приведенной в описании. Указанные в описании производные, смесь их изомеров или отдельные изомеры и их соли могут представлять собой активное вещество фармацевтической композиции с антагонистической в отношении ангиотензина активностью.

Способ получения @ 1,3-ди-(бензимидазолил)-4,6-диамино @ -бензола

СПОСОБ ПОЛУЧЕНИЯ 1,3-да- ...

СПОСОБ ПОЛУЧЕНИЯ 1,1΄-ДИАЛКИЛ-2,2΄-ДИБЕНЗИМИДАЗОЛИЛОВ

Способ получения производных дибензимидазолилалканов

Способ получения 2-арил/алкил/ бензазолов

Verfahren zur Herstellung von Benzimidazolylidenverbindungen

HETEROZYKLISCH SUBSTITUIERTE BENZIMIDAZOLE, DEREN HERSTELLUNG UND ANWENDUNG

VERFAHREN ZUR HERSTELLUNG UND REINIGUNG VON 1,7'-DIMETHYL-2'-PROPYL-2,5'-BI-1H-BENZIMIDAZOL

VERFAHREN ZUR SYNTHESE DER BISBENZIMIDAZOLEN UND IHREN DERIVATEN.

Verfahren zur Herstellung von Diimidazolen

SUBSTITUIERTE PHENYLPROPIONSÄUREDERIVATE ALS AGONISTEN FÜR DEN HUMANEN PEROXISOMPROLIFERATORAKTIVIERTEN REZEPTOR ALPHA (PPAR)

Sensibilisierung von photographischen Silberhalogenidemulsionen

Electrophotographic materials

Photoconductive compositions as in Specification 964,873 use as photoconductive compounds pyrroles, pyrrolines, pyrrolidines, indoles, indolenines, indolines and naphthopyrrolines, including substituted derivatives and cyanine and merocyanine dyes derived from such. Many typical compounds are mentioned. The sensitizing dyestuffs, resins and auxiliary materials mentioned in Specification 964,873 may be used. Specified resins are polyvinyl formal and butyral, polyvinyl-carbazole and a terpolymer of vinyl chloride, vinyl acetate and maleic anhydride. Specifications 856,770, 883,312, 916,660 and 964,871 also are referred to.ALSO:A cyanine dye of the formula is made by reacting 3-ethyl-2-methyl-benzthiazolium iodide with N-methylisatin-a -anil. Specifications 344,409, 354,898, 428,222, 428,359, 428,360, 633,824, 856,770, 883,312, 916,660, 964,871 and 964,875 are referred to.

SILVER HALIDE LIGHT-SENSITIVE PHOTOGRAPHIC MATERIALS

Preparation of 1,2-Di(aryl)ethylenes

... 1,164,648. 1,2-Di-(aryl) ethylenes. EASTMAN KODAK CO. 20 Oct., 1966 [20 Oct., 1965], No. 46914/66. Heading C5E. [Also in Division C2] 1,2-Di-(aryl) ethylenes are prepared by heating one or more mono-aryl methanes at reaction temperatures with, as an inorganic oxidant, As 2 O 5 , Sb 2 O 5 , Bi 2 O 3 , SbO 4 or manganese arsenate or mixtures thereof, or a substance or substances giving rise to said oxidant on heating at or below said reaction temperature. Reaction may be effected at 200-600‹ C. with the monoaryl methane in liquid or vapour form. The inorganic oxidant may be supported on e.g. alumina, silica, titania or kieselguhr and may be re-oxidized periodically or by continuous or intermittent removal of part of the oxidant during the reaction, re-oxidation thereof and return thereof continuously or intermittently. The preparation of stilbene is described in Examples 1, 2 and 11. 4,41-Diphenyl-stilbene, 1 - naphthyl - 2 - phenyl - ethylene and 1- (naphth - 21 - yl) - ...

BIS-BENZIMIDAZOLYL-SULPHONES

... 1377969 Bis-benzimidazolyl-sulphones E R SQUIBB & SONS Inc 8 Dec 1971 [11 Dec 1970] 57093/71 Heading C2C Novel compounds (I) (including salts thereof) where R is OH, alkoxy, amido, amino, mono- or di-alkyl amino, -NHCOOR3 (where R3 is alkyl, aryl or cycloalkyl), alkyl, NO 2 , ureido, SCN, halo, aralkyl, SH, aryl or alkaryl, R1, R2 and R21 are H, alkyl, acyl or optionally substituted aryl, m is 1 or 2, n is 0 or 1, n1 is 0 to 4 and n+n1 is 4 or less are obtained by reacting (II) with (III) (or with the corresponding sulphide and thereafter oxidizing the product obtained to give (I) via the sulphoxide). Pharmaceutical preparations showing anthelmintic action contain (I) as active ingredient. Administration is preferably orally.

Improvements relating to the production of benzimidazolylidene compounds and the resulting products

Benzimidazolylidene compounds are prepared by condensing a benzimidazole-2-aldehyde, unsubstituted in the benzene ring, with an organic compound containing an activated methyl or methylene group and having the general formula X-CH2-Y as hereinafter defined, if necessary in the presence of an acid or basic condensation catalyst, with splitting off of water. The organic compounds containing an activated methyl or methylene group are those in which X represents an electrophilic group such as a carbonyl, carboxyl, carboxylic ester, carboxylic amide, cyano, nitro or organic ammonium group, an aromatic-heterocyclic containing tertiary nitrogen, or a negatively substituted-aromatic isocyclic radical, and Y represents hydrogen, an inert organic group or an electrophilic group. Specified compounds include acetophenone, phenylacetic acid, benzyl cyanide, cyano acetic esters and amides, open and cyclic 1:3-diketones, malonic esters and amides including cyclic amides such as 1:3-diketo pyrazolidines ...

A process and products for the improvement of the optical properties of organic material

Compounds of general formula in which A is an aromatic nucleus which may be substituted and in which 2 adjacent carbons are linked directly to B and the group B is sulphur or the group in which R1 is H or an organic substituent, R is an organic substituent, R2 is an organic substituent having at least 3 conjugated double bonds which are also in conjugation with the >C=N bond of the heterocyclic ring, and X is an acid residue, may be used in conjunction with washing agents for the treatment of organic materials. Suitable washing agents are, for example, soaps; salts of sulphonate washing agents, such as sulphonated benzimidazoles substituted on the 2-carbon atom by high alkyl radicals; salts of monocarboxylic acid esters of 4-sulphophthalic acid with high fatty alcohols; salts of fatty alcohol sulphonates; alkylaryl sulphonic acids; or condensation products of high fatty acids with aliphatic hydroxy or amino sulphonic acids.

Method of preparation of (a)-benzimidazoles carrying basic substituents.

HETERO-CYCLIC RADICAL OR DIRADIKAL, THEIR DIMERE, OLIGOMERE, POLYMERS, DISPIROVERBINDUNGEN AND POLYCYCLEN, THEIR USE, ORGANIC SEMICONDUCTING MATERIAL AS WELL AS ELECTRONIC ELEMENT

VERFAHREN ZUR HERSTELLUNG VON NEUEN IMIDAZOLYL- (2) -CARBINOLEN UND IHREN SALZEN

PROCEDURE FOR the PRODUCTION AND CLEANING OF 1,7 ' - DIMETHYL-2' PROPYL-2,5' BI-1H-BENZIMIDAZOL

PROCEDURE FOR THE PRODUCTION OF TELMISARTAN

ANTIVIRAL COMPOSITIONS AND PROCEDURES FOR YOUR USE

N, N' DI (ARALKYL) - N, N' DI (2 - AZAARALKYL) of ALKYL DIAMINE DERIVATIVES AND YOUR USE IN PHARMACEUTICAL AND COSMETIC COMPOSITIONS

PROCEDURE FOR THE PRODUCTION OF UNTIL BENZAZOLYL CONNECTIONS

SUBSTITUTED PHENYLPROPIONSÄUREDERIVATE AS AGONISTEN FOR THE HUMAN PEROXISOMPROLIFERATORAKTIVIERTEN RECEPTOR ALPHA (PPAR)

CHINONVERBINDUNGEN FOR THE TREATMENT OF DISEASES

PROCEDURE FOR THE PRODUCTION OF 2 - ARYLBENZIMIDAZOLSULFONSÄUREN

OLIGOBENZIMIDAZOLDERIVATE AND YOUR USE AS DNA TRANSFEKTIONSMITTEL

POLYMORPHE OF TELMISARTAN, PROCEDURES FOR THEIR PRODUCTION AND THEIR USE FOR THE PRODUCTION OF A DRUG

COMPOSITIONS AND METHODS FOR THE PREVENTION OF CELL DEATH

4,5,6,7-TETRAHYDROBENZIMIDAZOLES ARE SEROTONIN RECEPTOR ANTAGONISTS AS PHARMACEUTICALS

Photoelectric conversion device wherein dye consisting of binuclear ruthenium complex having substituted bipyridyl groups is used, and photochemical cell

A dye consisting of a binuclear ruthenium complex having substituted bipyridyl groups, said binuclear ruthenium complex being represented by general formula (1) [wherein R, R, R and R are each independently straight-chain or branched C alkyl, with the proviso that R and/or R is straight-chain or branched C alkyl and R and/or R is straight-chain or branched C alkyl; X is a counter ion; and n represents the number of counter ions that is necessary to neutralize the electric charge of the complex, with the proviso that the proton (H) of one or more of the carboxyl (-COOH) groups may be in a dissociated state].

New material for transporting electrons and organic electroluminescent display using the same

Pesticidal cyanine dye derivatives

Antiviral compositions and method for their use

Antifungal activity of dicationic molecules

Protease inhibitors

Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase

Potassium channel blocking agents

Compositions and methods for inhibiting cell death

SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR)

The present invention provides the S enantiomer of a compound of formula (I) wherein n is 1 or 2 as well as pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof, to processes for preparing such compounds, to their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

NAPHTALENE OR HETEROCYCLICALLY SUBSTITUTED BENZIMIDAZOLES AS PARP INHIBITORS

The present invention relates to novel benzimidazoles, the production thereof and the utilisation as inhibitors of the enzyme poly(ADP-ribose)polymerase or PARP (EC 2.4.2.30) for producing medicaments.

N-SUBSTITUTED BENZIMIDAZOLE-2-CARBOXANILIDES, USE THEREOF AS LIGHT STABILIZERS, IN PARTICULAR FOR POLYMERS, AND ORGANIC MATERIAL CONTAINING SAME

Compounds of the general formula (I) (I) where R1 and R2 are each H, C1, alkyl, alkoxy, substituted or unsubstituted phenyl or phenylalkyl, R3 and R4 are each H, alkyl, oxaalkyl, alkoxy, oxaalkoxy, substituted or unsubstituted phenyl, phenylalkyl, phenoxy, phenylalkoxy, alkylcarbonylamino, benzoylamino, alkanoyloxy or benzoyloxy, n is 1 or 2 and R5 is - when n is 1 - alkyl, hydroxyalkyl, cycloalkyl, alkenyl, oxaalkyl, phenylalkyl or or or - when n is 2 - alkylene, cycloalkylene, alkenylene, oxaalkylene or or where m is from 2 to 4, R6 is alkyl, alkenyl, cycloalkyl, phenylalkyl, substituted or unsubstituted phenyl or naphthyl, and R7 is alkylene, alkenylene, cycloalkylene, substituted or unsubstituted phenylene, naphthylene, diphenylene, and are effective light stabilizers for organic materials, in particular for polymers.

OLIGOBENZIMIDAZOLE DERIVATIVES AND THEIR USE AS DNA TRANSFECTION AGENTS

L'invention se rapporte à des dérivés d'oligobenzimidazoles capables de s'associer avec les acides nucléiques de formule générale (I) dans laquelle R représente un atome d'hydrogène ou certains substituents, n est un entier égal à 2, 3, 4 ou 5 et R' représente un groupe -O-R3, -S-R3, NHR3, ou bien -O-CO-NH- R3 et R3 représente un groupe alkyle, ou bien R' représente un groupe -NR4R5 ou bien -O-CO-NR4R5 et R4 et R5 représentent chacun un groupe alkyle, les radicaux alkyles contenant 12 à 22 atomes de carbone, leurs sels, les compositions qui les contiennent et leurs utilisations, par exemple pour le transfert in vitro, in vivo ou ex vivo d'acides nucléiques dans les cellules ou la visualisation des acides nucléiques administrés par fluorescence.

ENERGY TRANSFER ASSAY METHOD AND REAGENT

Disclosed is a non-fluorescent cyanine dye that may be used as an acceptor in fluorescence energy transfer assays involving the detection of binding and/or cleavage events in reactions involving biological molecules, and assay methods utilising such dyes. The non-fluorescent cyanine dye is a compound of formula (I), wherein the linker group Q contains at least one double bond and forms a conjugated system with the rings containing X and Y; groups R3, R4, R5 and R6 are attached to the rings containing X and Y, or optionally, are attached to atoms of the Z1 and Z2 ring structures; Z1 and Z2 each represent a bond or the atoms necessary to complete one or two fused aromatic rings each ring having five or six atoms, selected from carbon atoms and, optionally, no more than two oxygen, nitrogen and sulphur atoms; at least one of groups R1, R2, R3, R4, R5, R6 and R7 is a target bonding group; any remaining groups R3, R4, R5, R6 and R7 groups are independently selected from the group consisting ...

HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS

The present invention provides compounds (1) to (6) capable of modulating tyrosine kinases, compositions comprising the compounds and methods of their use (Formulaes I to VI).

LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS

Herein are provided compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds may be used to treat infectious disease, autoimmune disease, diabetes, or a chronic inflammatory disease. Exemplary compound are those of general formula 111-66: or a pharmaceutically acceptable salt or ester thereof.

RETROVIRAL PROTEASE INHIBITORS DERIVED FROM 3-CHLORO-2-CHLOROMETHYL-1-PROPENE

... 31,560 Title- RETROVIRAL PROTEASE INHIBITORS DERIVED FROM 3-CHLORO-2-CHLORO- METHYL-1-PROPENE BACKGROUND OF THE INVENTION The invention provides compounds of the formula: wherein Q, X, Y, Z, R1, R2 and R3 are defined in the specifications useful as inhibitors of HIV protease enzyme.

USE OF BIS(AMIDINOBENZIMIDAZOLES) IN THE MANUFACTURE OF MEDICAMENT FOR INHIBITING RETROVIRAL INTEGRASE

Disclosed is a method of inhibiting retroviral integrase in a subject in need of such treatment. The method comprises administering to the subject an effective retroviral integrase inhibiting amount of a bis-benzimidazole compound such as bis [5- amidino-2-benzimidazolyl] methane, 1,2-bis [5-amidino-2- benzimidazolyl] ethane, 1, 2-bis [5-amidino-2- benzimidazolyl] ethene or a pharmaceutically acceptable salt thereof. A method for combatting retroviral infections is also disclosed.

Verfahren zur Herstellung eines neuen a,B-Di-(benzimidazyl-(2))-äthylens.

Verfahren zur Herstellung eines neuen a,B-Di-(benzimidazyl-(2))-äthylens.

Verfahren zur Herstellung eines neuen a,B-Di-(benzimidazyl-(2))-äthylens.

Verfahren zur Herstellung eines neuen a,B-Di-(benzimidazyl-(2))-äthylens.

Verfahren zur Herstellung eines a,ss-Di-(benzimidazyl-(2))-äthylens.

Verfahren zur Herstellung des a,B-Di-(benzimidazyl-(2))-äthylens.

Verfahren zur Herstellung eines neuen Benzimidazolderivates.

Verfahren zur Herstellung des neuen a,B-Di-(N-benzyl-benzimidazyl-(2))-äthylens.

Verfahren zur Herstellung des neuen a,B-Di-(N-methyl-benzimidazyl-(2))-äthylens.

Verfahren zur Herstellung eines neuen Benzimidazolderivates.

Verfahren zur Herstellung des neuen 2,5-Di-(benzimidazyl-(2))-furans.

Verfahren zur Herstellung des a-(Benzimidazyl-(2))-B-(N-methyl-benzimidazyl-(2))-äthylens.

Verwendung von Di-imidazolen zum optischen Aufhellen von Materialien aus Acrylnitrilpolymerisaten

Verwendung von neuen Azol-Derivaten als optische Aufheller für textile organische Materialien

Verwendung von neuen Poly-azolen als optische Aufhellmittel für textile organische Materialien

Verfahren zur Herstellung von a,B-Di-arylimidazyl-äthylenverbindungen

Verfahren zur Herstellung neuer Imidazoliumverbindungen

Verfahren zur Herstellung von Diimidazolderivaten

Verfahren zur Herstellung von Diimidazolderivaten

Verfahren zur Herstellung von Druckplatten

Verfahren zur Herstellung von a,ss-Di-(arylazolyl)-äthylenen

Verfahren zur Herstellung von Diimidazolderivaten

Verfahren zur Herstellung von Benzimidazolen

Verfahren zur Herstellung neuer Pyrrolderivate

Verfahren zur Herstellung von Furanderivaten

Verfahren zur Herstellung von a,B-Di-(imidazyl-(2))-äthylenen

Verfahren zur Herstellung neuer Diimidazolderivate

Verfahren zur Herstellung neuer Imidazoliumverbindungen

Verfahren zur Darstellung einer Azolverbindung.

Procédé de préparation de composés azoliques

Verwendung von neuen Bis-azolen als optische Aufhellmittel ausserhalb der Textilindustrie

Napththylene-bis-2-benzimidazoles as optical

Naphthylene-bis-2-benzimidazoles as optical brighteners New cpds:- (where R = naphthylene; R' = H, alkyl, aralkyl, aryl, opt. substd.; R2 and R3 = H, halo, alkyl, alkoxy, aryl or COOH or SO3H or derivs. thereof, or R2 + R3 = C3-4 alkylene or a fused ring aromatic gp.) are prepd. by reaction (i) of 1 mol. of a naphthylene dicarboxylic acid (or a deriv.) with 2 mols or slighty more of an o-diamino benzene deriv. in the presence of a catalyst at 100 - 250 degrees C in the absence of oxygen, or (ii) of 1 mol. of a naphthalene dicarboxylic acid dichloride with 2 mols or slightly more of an o-nitroaniline deriv., reduction of the NO2 right arrows NH2 and ring closure.

Verwendung von neuen Tolanderivaten als optische Aufhellmittel ausserhalb der Textilindustrie

Verfahren zum optischen Aufhellen von Polyacrylnitril-Fasermaterialien

Verwendung von neuen Azol-Derivaten als optische Aufhellmittel ausserhalb der Textilindustrie

Verwendung von neuen Poly-azolen als optische Aufhellmittel ausserhalb der Textilindustrie

Basically substd bis-benzimidazole derivs anthelmintics bacteriostats

Cmpds. Ar = arylene R' = H, halogen, OH, (1-4C) alkyl, (1-4C) alkoxy, SH, (1-4C) alkylS-, alkylendioxy, NO2, Ph, or NH2 opt. subst. by (1-4C) alkyl. R2 = H, opt. subst. alkyl, carbalkoxy, carbamido, aryl, or aralkyl R3 = halogen, (1-4C) alkyl, or (1-4C) alkoxy - Acid addn. salts of (I). - a) Anthelmintics, esp. active against filaria Litosomoides carinii etc. - b) Bacteriostats.

Procédé de préparation de nouveaux dérivés du bis-benzimidazole

Procédé de préparation de bis-benzimidazoyl-sulfones

PROCESS FOR MANUFACTURE OF TELMISARTAN

A process for preparing telmisartan by reacting 2-n-propyl-4-methyl-6-(1′-methylbenzimidazol-2′-yl)benzimidazole with a compound of formula (IV) 128-. (canceled)30. The process according to claim 29 , wherein the product of step (a) is worked up before step (b) is performed.31. The process according to claim 29 , wherein the telmisartan product of step (b) is worked up and converted into the hydrochloride.32. The process according to claim 29 , wherein the product of step (a) is worked up before step (b) is performed and the telmisartan product of step (b) is worked up and converted into the hydrochloride.33. The process according to claim 29 , wherein Z is a halogen atom or a substituted sulfonyloxy group.34. The process according to claim 29 , wherein Z is a bromine atom.35. The process according to claim 29 , wherein the first solvent is selected from methylene chloride claim 29 , diethyl ether claim 29 , tetrahydrofuran claim 29 , dioxane claim 29 , dimethylsulfoxide claim 29 , dimethylformamide claim 29 , dimethylacetamide claim 29 , dimethylformamide/tert-butanol claim 29 , dimethylacetamide/tert-butanol claim 29 , toluene claim 29 , benzene claim 29 , or a mixture thereof.36. The process according to claim 35 , wherein step (a) is carried out in the presence of an acid-binding agent.37. The process according to claim 36 , wherein the acid-binding agent is selected from sodium carbonate claim 36 , potassium carbonate claim 36 , sodium hydroxide claim 36 , potassium hydroxide claim 36 , sodium methoxide claim 36 , potassium methoxide claim 36 , potassium tert-pentoxide claim 36 , potassium tert-butoxide claim 36 , potassium n-butoxide claim 36 , sodium hydride claim 36 , triethylamine claim 36 , and pyridine.38. The process according to claim 29 , wherein step (a) is carried out at a temperature between 0° C. and 100° C.39. The process according to claim 30 , wherein step (a) is carried out at a temperature between 0° C. and 100° C.40. The process according to ...

PROCESS FOR PREPARING BENZOIC ACID ESTERS

There is provided a more industrially advantageous process for preparing novel pyridine derivatives expected to be used as medicines. A process for preparing 3-[(6-hydroxy-1-methyl-1H-benzimidazol-2-yl)methoxy]benzoic acid esters as intermediates with high quality, in short steps and in a high yield, as well as novel benzoic acid esters as their precursors and a process for preparing the same. 2. The preparation process according to claim 1 , wherein A is a methyl group.3. The preparation process according to claim 1 , wherein B is a phenyl group.4. The preparation process according to claim 1 , wherein the solvent is a halogenated hydrocarbon claim 1 , a nitrile claim 1 , an ether or a mixed solvent thereof.5. The preparation process according to claim 1 , wherein the solvent is tetrahydrofuran.6. The preparation process according to claim 1 , wherein the solvent is a halogenated hydrocarbon claim 1 , a nitrile claim 1 , an ether claim 1 , an amide claim 1 , a carboxylate or a mixed solvent thereof.7. The preparation process according to claim 1 , wherein the solvent is N claim 1 ,N-dimethylacetamide.8. The preparation process according to claim 1 , wherein the preparation process proceeds in the presence of a halogenating agent.9. The preparation process according to claim 8 , wherein the halogenating agent is thionyl chloride claim 8 , oxalyl chloride or phosphorus pentachloride.10. The preparation process according to claim 8 , wherein the halogenating agent is thionyl chloride.11. The preparation process according to claim 8 , wherein the compound represented by the general formula (1) and the compound represented by the general formula (2) are previously mixed and the halogenating agent is added thereto.12. The preparation process according to claim 1 , wherein the preparation process proceeds in the presence of a base.13. The preparation process according to claim 12 , wherein the base is an alkali metal hydride.14. The preparation process according to claim ...

Capsule-type Compound, Anion Removing Agent, and Method for Removing Anion

The present invention provides a capsule-type compound consisting of: a capsule-type divalent cation consisting of a capsule framework represented by the following formula (1) and a sulfate ion (SO) encapsulated in the capsule framework; and a sulfate ion (SO) as a counter ion to the capsule-type divalent cation. In the formula (1), R, R, R, R, R, R, R, R, R, R, R, R, and Reach independently represent a hydrogen atom or a methyl group; and Mand Meach independently represent Cu, Fe, Ni, Co, or Zn. 2. The capsule-type compound according to claim 1 , wherein Mand Mare the same.3. The capsule-type compound according to claim 1 , wherein Mand Mare Cu.4. The capsule-type compound according claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare all hydrogen atoms.5. An anion removing agent comprising claim 1 , as an active component claim 1 , the capsule-type compound according .6. A method for removing an anion claim 1 , comprising a step of bringing a water-based sample containing water and at least one anion selected from the group consisting of ClO claim 1 , BF claim 1 , NO claim 1 , Br claim 1 , and I claim 1 , and the capsule-type compound according to into contact with each other to remove the anion from the water-based sample.7. The method for removing an anion according to claim 6 , wherein the water-based sample contains at least ClO. The present invention relates to a capsule-type compound, an anion removing agent, and a method for removing an anion.A perchlorate ion (ClO), a tetrafluoroborate ion (BF), a nitrate ion (NO), and a bromide ion (Br) have high solubility in water, although being harmful ions, and are therefore anions that are difficult to remove from aqueous solutions. In addition to the anions, an iodide ion (I) also has high solubility in water and is an anion that is difficult to remove from aqueous solutions.For example, it has been ...

Antiviral Drugs for Treatment of Arenvirus Infection

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the family is disclosed. 2. The composition of claim 1 , wherein that at least one of B claim 1 , D claim 1 , E claim 1 , G claim 1 , B′ claim 1 , D′ claim 1 , E′ and G′ is C—Y claim 1 , wherein Y is halogen.3. (canceled)4. The composition of claim 1 , wherein R is selected from the group consisting of hydrogen claim 1 , alkyl claim 1 , amino and halogen.5. The composition of claim 1 , wherein claim 1 , R is hydrogen or methyl.6. The composition of claim 1 , wherein each of X and X′ is N—R′.7. The composition of claim 6 , wherein R′ is hydrogen or alkyl.8. The composition of claim 1 , wherein the compound of Formula I is selected from the group consisting of 1H claim 1 ,1′H-[2 claim 1 ,2′]Bibenzoimidazolyl; 5 claim 1 ,6 claim 1 ,5′ claim 1 ,6′-Tetramethyl-1H claim 1 ,1′H-[2 claim 1 ,2′]bibenzoimidazolyl; 1 claim 1 ,1′-Dimethyl-1H claim 1 ,1′H-[2 claim 1 ,2′]bibenzoimidazolyl; 1 claim 1 ,1′-Diethyl-1H claim 1 ,1′H-[2 claim 1 ,2′]bibenzoimidazolyl; 6 claim 1 ,6′-Dinitro-1H claim 1 ,1′H-[2 claim 1 ,2′]bibenzoimidazolyl; 4 claim 1 ,4′-Difluoro-1H claim 1 ,1′H-[2 claim 1 ,2′]bibenzoimidazolyl; 5 claim 1 ,5′-Difluoro-1H claim 1 ,1′H-[2 claim 1 ,2′]bibenzoimidazolyl; 5 claim 1 ,5′-Dichloro-1H claim 1 ,1′H-[2 claim 1 ,2′]bibenzoimidazolyl; 5 claim 1 ,5′-Dibromo-1H claim 1 ,1′H-[2 claim 1 ,2′]bibenzoimidazolyl; 4 claim 1 ,4′-Dimethyl-1H claim 1 ,1′H-[2 claim 1 ,2′]bibenzoimidazolyl; 5 claim 1 ,5′-Dimethyl-1H claim 1 ,1′H-[2 claim 1 ,2′]bibenzoimidazolyl; 4 claim 1 ,4′-Dimethoxy-1H claim 1 ,1′H-[2 claim 1 ,2′]bibenzoimidazolyl; 5 claim 1 ,5′-Dimethoxy-1H claim 1 ,1′H-[2 claim 1 ,2′]bibenzoimidazolyl; ...

ANTHRACENE DERIVATIVES CONTAINING BENZIMIDAZOLE OR BORATE AND ORGANOELECTROLUMINESCENT DEVICE INCLUDING THE SAME

An organic light-emitting diode comprises a first electrode layer, a second electrode layer, and an organic luminescent unit disposed between the first electrode layer and the second electrode layer. The organic luminescent unit has an organic electroluminescent material containing anthracene group as shown in General Formula (1): 2. The organic light-emitting diode according to claim 1 , wherein the alkyl group is selected from the group consisting of a substituted or unsubstituted straight-chain C1˜C6 alkyl group claim 1 , and a substituted or unsubstituted branched-chain C3˜C6 alkyl group claim 1 , the cycloalkyl group is a substituted or unsubstituted C3˜C6 cycloalkyl group claim 1 , the alkoxy group is selected from the group consisting of a substituted or unsubstituted straight-chain C1˜C6 alkoxy group claim 1 , and a substituted or unsubstituted branched-chain C3˜C6 alkoxy group claim 1 , the haloalkyl group is selected from the group consisting of a substituted or unsubstituted straight-chain C1˜C6 haloalkyl group claim 1 , and a substituted or unsubstituted branched-chain C3˜C6 haloalkyl group claim 1 , the thioalkyl group is selected from the group consisting of a substituted or unsubstituted straight-chain C1˜C6 thioalkyl group claim 1 , and a substituted or unsubstituted branched-chain C3˜C6 thioalkyl group claim 1 , the silyl group is selected from the group consisting of a substituted or unsubstituted straight-chain C1˜C6 silyl group claim 1 , and a substituted or unsubstituted branched-chain C3˜C6 silyl group claim 1 , and the alkenyl group is selected from the group consisting of a substituted or unsubstituted straight-chain C2˜C6 alkenyl group claim 1 , and a substituted or unsubstituted branched-chain C3˜C6 alkenyl group.4. The organic light-emitting diode of claim 1 , wherein the organic luminescent unit comprises an organic luminescent layer.5. The organic light-emitting diode of claim 4 , wherein the organic luminescent unit further comprises a ...

TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS

Compounds, compositions, and methods for the treatment of infections caused by or trophozoites and/or cysts and for the disinfection of solids and/or liquids, such as medical and personal care items, for example contact lenses, that may harbor trophozoites and/or cysts are provided. 2. The compound of claim 1 , wherein one of Rand Ris a halogen.3. The compound of claim 1 , wherein two of Rand R claim 1 , R claim 1 , Rand Rare selected from a halogen.4. The compound of claim 1 , wherein two of R claim 1 , R claim 1 , R claim 1 , Rand Rare selected from a halogen.5. The compound claim 1 , wherein one of R claim 1 , R claim 1 , R claim 1 , and Ris selected from C-Calkoxy.6. The compound of claim 1 , wherein Rand Rare isopropyl.14. The compound of claim 13 , wherein Ris independently at each occurrence selected from hydrogen claim 13 , C-Calkyl claim 13 , and C-Ccycloalkyl.17. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof claim 1 , optionally in a pharmaceutically acceptable carrier.18Acanthamoeba. A method for the treatment of an eye infection caused by one gr more species in a host in need thereof comprising administering an effective amount of a compound of claim 1 , optionally in a pharmaceutically acceptable carrier.19Acanthamoeba. A method for the disinfection of one or more species from a solid claim 1 , liquid or gel object comprising administering an effective amount of a compound of claim 1 , optionally in a pharmaceutically acceptable carrier.20. The method of claim 19 , wherein the object is selected from an application claim 19 , a dressing claim 19 , contact lens claim 19 , an optical implant claim 19 , a contact lens solution claim 19 , an ocular solution and rewetting eye drops.21Acanthamoeba. The method of wherein the eye infection is keratitis.22. The method of claim 18 , further comprising administering an effective amount of an additional therapeutic agent selected from alexidine claim 18 , ...

COMPOUNDS, SENSORS, METHODS, AND SYSTEMS FOR DETECTING GAMMA RADIATION

Methods, compositions, and systems for detecting gamma radiation is disclosed and described. A compound for detecting gamma radiation can comprise a conjugated imidazole having the following structure: [Formula I] where at least one of R1, R2, and R3 are conjugated organic groups. Additionally, the conjugated imidazole can be capable of reacting with a radical or ion formed by the reaction of gamma radiation with a radical generating component such as a halogen solvent to decrease a molar extinction coefficient of the conjugated imidazole in the visible light region or to quench fluorescence of the conjugated imidazole. As a sensor (100), a radiation detection indicator (108) can indicate the change in molar extinction coefficient or fluorescence of the conjugated imidazole material (120) upon exposure to gamma radiation. 2. The sensor of claim 1 , wherein each of R1 claim 1 , R2 claim 1 , and R3 are conjugated organic groups.7. The sensor of claim 1 , wherein the conjugated imidazole is selected from the group consisting of 4 claim 1 ,4′-Bis(1H-phenanthro[9 claim 1 ,10-d]imidazol-2-yl)phenyl (“BPI-Ph”); 4 claim 1 ,4′-Bis(1H-phenanthro[9 claim 1 ,10-d]imidazol-2-yl)biphenyl (“BPI-BP”); 1 claim 1 ,4-bis(4 claim 1 ,5-diphenyl-1H-imidazol-2-yl)benzene (BDPI-Ph); 4 claim 1 ,4′-bis(4 claim 1 ,5-diphenyl-1H-imidazol-2-yl)biphenyl (BDPI-BP): 2 claim 1 ,2′-(9 claim 1 ,9-bis(2-ethylhexyl)-9H-fluorene-2 claim 1 ,7-diyl)bis(1H-phenanthro[9 claim 1 ,10-d]imidazole) (BPI-Flu); 2 claim 1 ,2′-(9-(2-ethylhexyl)-9H-carbazole-2 claim 1 ,7-diyl)bis(1H-phenanthro[9 claim 1 ,10-d]imidazole) (BPI-Cb); tris(4-(1H-phenanthro[9 claim 1 ,10-d]imidazol-2-yl)phenyl)amine (PI-TPA); 2-phenyl-1H-phenanthro[9 claim 1 ,10-d]imidazole (PI-Ph); 2 claim 1 ,4 claim 1 ,5-triphenyl-1H-imidazole (TPI); 4-(1H-phenanthro[9 claim 1 ,10-d]imidazol-2-yl)-N claim 1 ,N-diphenylaniline (PI-DPA); N claim 1 ,N-dimethyl-4-(1H-phenanthro[9 claim 1 ,10-d]imidazol-2-yl)aniline (PI-DMA); and combinations thereof.8. The ...

BENZIMIDAZOLE SUBSTITUTION-BASED PHENYL N-BUTYRAMIDE COMPOUND AND PREPARATION METHOD THEREFOR

The present disclosure relates to a benzimidazole-substituted phenyl-n-butyramide-based compound and the preparation method thereof. The method of the present disclosure avoids nitration reaction and polyphosphoric acid cyclization reaction, and avoids the generation of a large amount of waste acid reaction solution from the source. The synthesis method embodied in the invention has the advantages of simplicity and high efficiency, mild conditions and few pollutants, etc., and is suitable to be developed as a green and sustainable production process. 4. The method according to claim 2 , wherein the method Five is conducted according to one of the following three methods:{'sub': '3', 'Method (a), when Ris chlorine, or bromine, or n-butyryloxy, reacting the compound of formula VI with n-butyryl chloride, or n-butyryl bromide, or n-butyric anhydride to prepare the compound of formula III,'}In particular, method (a) is conducted in presence of a basic reagent, the basic reagent is one selected from the group consisting of lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, sodium phosphate, potassium phosphate, sodium monohydrogen phosphate, potassium monohydrogen phosphate, lithium hydroxide, sodium hydroxide, potassium hydroxide, magnesium carbonate, magnesium hydroxide, calcium carbonate, calcium hydroxide, calcium oxide, magnesium oxide, lithium methoxide, sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, lithium isopropoxide, sodium isopropoxide, potassium isopropoxide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, magnesium methoxide, magnesium ethoxide, magnesium tert-butoxide, ammonia water, triethylamine, diisopropylamine, diisopropyl ethyl amine, tri-n-butyl amine, pyridine, 2-methylpyridine, 2,6-dimethylpyridine, 4-dimethylaminopyridine, tetrahydropyrrole, morpholine, piperidine and 2,2,6,6-tetramethylpiperidine; or a mixture thereof;In ...

NOVEL COMPOUND AND METHOD FOR PRODUCING SAME

A compound represented by the formula (1) is provided: 2. The compound according to claim 1 , wherein both of two Aare —NR—.4. The compound according to claim 1 , wherein Ris a hydrogen atom.5. A composition comprising the compound according to and an electron-transporting material.6. A composition comprising the compound according to claim 5 , further comprising a solvent.8. The method according to claim 7 , wherein{'sup': '4', 'Ris a hydrogen atom, and'}{'sup': '2', 'Mis an aluminum atom.'} The present invention relates to a novel compound and a method for producing the same.In recent years, research on various electronic devices such as organic light-emitting diodes (OLED), polymer light-emitting diodes (PLED), organic photovoltaics (OPV), and organic thin film transistors (OTFT) using ultrathin films of organic materials has been actively made. For these electronic devices, methods using doping materials are known as methods for improving conductivity.For example, an organic thin film transistor using N-DMBI as an n-type doping material is disclosed in Non Patent Literature 1; an organic light-emitting diode using N-DMBI as an n-type doping material is disclosed in Patent Literature 1; and an n-type dopant precursor for doping an organic semiconductor material is disclosed in Patent Literature 2.However, sufficient findings on stable n-type doping materials that permit film formation by a coating method have not yet been obtained. For example, compounds described as n-type doping materials in the cited literatures mentioned above did not always have sufficient electron-donating ability.Accordingly, an object of the present invention is to provide a novel compound that can be suitably used as a strong n-type doping material, and a method for producing the same.The present invention provides the following [1] to [9]:[1] A compound represented by the formula (1):whereinArepresents an oxygen atom, a sulfur atom, —NR— or —PR—; two Aare the same as or different from ...

ORGANIC COMPOUND, FIELD ELEMENT, ORGANIC LIGHT-EMITTING ELEMENT, DISPLAY APPARATUS, IMAGE INFORMATION-PROCESSING APPARATUS, LIGHTING APPARATUS, IMAGE-FORMING APPARATUS, AND EXPOSURE APPARATUS

A bibenzo[d]imidazolidene compound inert to oxygen is provided. A 1,1′,3,3′-tetraphenyl-2,2′-bibenzo[d]imidazolidene compound is represented by general formula (1). In formula (1), Rto Rare each independently selected from a hydrogen atom and a substituent. The substituent is any of a halogen atom, an alkyl group containing 1 or more and 8 or less carbon atoms, and a substituted or unsubstituted aryl group. At least one of Rto Ris the substituent. 2. The organic compound according to claim 1 , wherein at least one of the Rto the Rand the Rto the Ris any of an alkyl group containing 1 or more and 8 or less carbon atoms and a phenyl group.3. The organic compound according to claim 1 , wherein at least one of the R claim 1 , the R claim 1 , the R claim 1 , and the Ris any of an alkyl group containing 1 or more and 8 or less carbon atoms and a phenyl group.4. The organic compound according to claim 1 , wherein at least one of the Rto the Rand the Rto the Ris any of a fluorine atom claim 1 , a tert-butyl group claim 1 , a sec-butyl group claim 1 , an isobutyl group claim 1 , and an isopropyl group with the Rto the Rand the Rto the Rbeing hydrogen atoms.7. The organic light-emitting element according to claim 6 , wherein at least one of the Rto the Ris the substituent.8. The organic light-emitting element according to claim 6 , wherein at least one of the Rto the Rand the Rto the Ris any of an alkyl group containing 1 or more and 8 or less carbon atoms and a phenyl group.9. The organic light-emitting element according to claim 6 , wherein each of the R claim 6 , the R claim 6 , the R claim 6 , and the Ris an alkyl group containing 1 or more and 8 or less carbon atoms or a phenyl group.10. The organic light-emitting element according to claim 6 , wherein at least one of the Rto the Rand the Rto the Ris any of a fluorine atom claim 6 , a tert-butyl group claim 6 , a sec-butyl group claim 6 , an isobutyl group claim 6 , and an isopropyl group with the Rto the Rand the Rto ...

TRANSCRIPTOME-WIDE DESIGN OF SELECTIVE, BIOACTIVE SMALL MOLECULES TARGETING RNA

Methods and computer systems are described herein for identifying small molecules that bind to selected RNA structural features (e.g., to RNA secondary structures). Also described are compounds and compositions that modulate RNA function and/or activity. 3. A method of modulating microRNA function or activity comprising claim 1 , contacting the microRNA with the compound of .4. The method of claim 3 , wherein the microRNA is a pre-microRNA-96 claim 3 , a pre-microRNA-210 claim 3 , or a pre-microRNA-182.5. A method of treating cancer in a subject claim 3 , comprising administering to the subject a compound of or a composition of claim 3 , to thereby treat cancer in the subject.7. The method of claim 6 , wherein the microRNA is pre-microRNA-96.9. The method of claim 8 , wherein the microRNA is pre-microRNA-210.11. The method of claim 10 , wherein the microRNA is microRNA-182.12. A method for identifying a compound that binds to an RNA claim 10 , comprising:(a) comparing a query dataset of RNA secondary structures from the RNA, with a dataset of identified bound RNA motif-small molecule pairs, to generate an output listing of pairs of identified RNA secondary structures and the identified small molecule that bind thereto;(b) obtaining an RNA with an identified RNA secondary structure and the identified small molecule that binds thereto;(c) determining a binding affinity of the identified RNA secondary structure with the identified small molecule that binds thereto by mixing an RNA having the RNA secondary structure with the identified small molecule and measuring the binding affinity, and/or determining whether the identified small molecule reduces or increases amounts of an RNA having the RNA secondary structure in a mammalian cell;to thereby identify a compound that binds to the RNA.13. The method of claim 12 , wherein the output listing of pairs of identified RNA secondary structures and the identified small molecule that binds thereto comprises one or more RNA ...

TRANSCRIPTOME-WIDE DESIGN OF SELECTIVE, BIOACTIVE SMALL MOLECULES TARGETING RNA

Methods and computer systems are described herein for identifying small molecules that bind to selected RNA structural features (e.g., to RNA secondary structures). Also described are compounds and compositions that modulate RNA function and/or activity. 3. A method of modulating microRNA function or activity comprising claim 1 , contacting the microRNA with the compound of .4. The method of claim 3 , wherein the microRNA is a pre-microRNA-96 claim 3 , a pre-microRNA-210 claim 3 , or a pre-microRNA-182.5. A method of treating cancer in a subject claim 2 , comprising administering to the subject the composition of claim 2 , to thereby treat cancer in the subject.7. The method of claim 6 , wherein the microRNA is pre-microRNA-96.9. The method of claim 8 , wherein the microRNA is pre-microRNA-210.11. The method of claim 10 , wherein the microRNA is microRNA-182.12. A method for identifying a compound that binds to an RNA claim 10 , comprising:(a) comparing a query dataset of RNA secondary structures from the RNA, with a dataset of identified bound RNA motif-small molecule pairs, to generate an output listing of pairs of identified RNA secondary structures and the identified small molecule that bind thereto;(b) obtaining an RNA with an identified RNA secondary structure and the identified small molecule that binds thereto;(c) determining a binding affinity of the identified RNA secondary structure with the identified small molecule that binds thereto by mixing an RNA having the RNA secondary structure with the identified small molecule and measuring the binding affinity, and/or determining whether the identified small molecule reduces or increases amounts of an RNA having the RNA secondary structure in a mammalian cell;to thereby identify a compound that binds to the RNA.13. The method of claim 12 , wherein the output listing of pairs of identified RNA secondary structures and the identified small molecule that binds thereto comprises one or more RNA sequence for each ...

ONE POT PROCESS FOR THE PREPARATION OF TELMISARTAN

A process for the preparation of bromine free telmisartan in one pot starting from 2-cyano-4′-methyl biphenyl. The process uses raw materials which are readily available to yield telmisartan, its salts and derivatives thereof, which are bromine free and potentially less genotoxic, since there is no bromine atom in any of the raw materials. 2. The process according to claim 1 , step (a) wherein the chlorination of compound of formula 1 is carried out using chlorine gas claim 1 , without a free radical initiator or a catalyst to give the compound of Formula 2.3. The process according to claim 1 , step (a) wherein the first solvent used for the chlorination is a halogenated hydrocarbon.4. The halogenated hydrocarbon of is preferably methylene chloride.5. The process according to wherein the chlorination is carried out at temperature between 15 to 35° C. without a free radical initiator or a catalyst.6. The process according to wherein the temperature for the chlorination reaction is between 20 to 25° C.7. The process according to claim 1 , step (b) wherein the second solvent is an aromatic hydrocarbon or a ketone.8. The process according to wherein the second solvent is selected from methyl isobutyl ketone claim 7 , toluene claim 7 , xylene or acetone.9. The process according to claim 1 , step (b) claim 1 , wherein the reaction of compound of Formula 2 with the compound of Formula 3 is in the presence of (a) phase transfer catalyst selected from a quaternary ammonium salt; (b) alkali metal hydroxide selected from sodium hydroxide or potassium hydroxide.10. The process according to wherein the base is preferably sodium hydroxide and the phase transfer catalyst is preferably tetrabutyl ammonium hydrogen sulphate.11. The process according to wherein temperature of the reaction for the preparation of compound of Formula 4 is between 50 to 110° C.12. The process according to claim 11 , wherein the temperature of the reaction is between 80 to 85° C. when the second solvent ...

Tandem Organic Light-Emitting Diode, Array Substrate and Display Device

A tandem organic light-emitting diode, an array substrate and a display device are provided. The tandem organic light-emitting diode includes an anode, a hole transport layer, a first light-emitting layer, a first charge generation layer, a second charge generation layer, a third charge generation layer, a fourth charge generation layer, a second light-emitting layer, an electron transport layer and a cathode which are sequentially laminated, wherein the first charge generation layer is an N-type bulk heterojunction, the second charge generation layer and the third charge generation layer are both PN junction type bulk heterojunctions, a proportion of the P-type organic material in the second charge generation layer is greater than that of the N-type organic material, a proportion of the P-type organic material in the third charge generation layer is less than that of the N-type organic material, and the fourth charge generation layer is a P-type bulk heterojunction. 1. A tandem organic light-emitting diode comprising an anode , a hole transport layer , a first light-emitting layer , a first charge generation layer , a second charge generation layer , a third charge generation layer , a fourth charge generation layer , a second light-emitting layer , an electron transport layer , and a cathode which are sequentially laminated ,wherein the first charge generation layer is an N-type bulk heterojunction, the second charge generation layer is a first PN junction type bulk heterojunction, the third charge generation layer is a second PN junction type bulk heterojunction, and the fourth charge generation layer is a P-type bulk heterojunction.2. The tandem organic light-emitting diode according to claim 1 , wherein the first charge generation layer comprises a mixture of a first organic material and a second organic material claim 1 , a proportion of the first organic material in the first charge generation layer is greater than a proportion of the second organic material ...

Amine derivatives, material for organic electroluminescent device comprising the same, and organic electroluminescent device using the same

A novel amine derivative, a material for an organic electroluminescent (EL) device capable of lowering the driving voltage and enhancing the emission efficiency of the organic EL device, and an organic EL device using the same. According to an embodiment of the present disclosure, an amine derivative is represented by following Formula 1:

Selective Inhibition of Bacterial Topoisomerase I

The present invention provides novel bisbenzimidazole compounds and methods of using the compounds as antibacterial agents. 2. The compound according to claim 1 , wherein X comprises a hydrophobic linker and a terminal alkyne group.3. The compound claim 2 , according to claim 2 , wherein the hydrophobic linker is a substituted or unsubstituted claim 2 , branched or unbranched claim 2 , saturated or unsaturated alkyl group.4. The compound claim 3 , according to claim 3 , wherein the alkyl group has 2 to 25 carbon atoms.5. The compound claim 4 , according to claim 4 , wherein the alkyl group has 2 to 15 carbon atoms.6. The compound claim 1 , according to claim 1 , wherein the derivative is a monobenzimidazole claim 1 , has the piperzine removed claim 1 , and/or has substituted aromatic rings.8. A pharmaceutical composition comprising the compound of claim 1 , and a pharmaceutically acceptable carrier or diluent.9. The pharmaceutical composition claim 8 , according to claim 8 , further comprising one or more additional antibiotic compounds.10. The pharmaceutical composition claim 9 , according to claim 9 , wherein the one or more additional antibiotic compound are selected from beta-lactams claim 9 , macrolides claim 9 , tetracyclines claim 9 , quinolones claim 9 , aminoglycosides claim 9 , sulfonamides claim 9 , glycopeptides claim 9 , and oxazolidinones.11. A method for treating a bacterial infection claim 1 , comprising administering claim 1 , to a subject in need of such treatment claim 1 , a compound of .12. A method of inhibiting topoisomerase I in bacteria claim 1 , comprising administering claim 1 , to the bacteria claim 1 , a compound of . This application claims the benefit of U.S. provisional application Ser. No. 61/879,968, filed Sep. 19, 2013, the disclosure of which is incorporated herein by reference in its entirety.New approaches for the discovery of antibacterial drugs are paramount to our efforts in the continuing fight against bacterial resistance. ...

POLYMERS DERIVED FROM 2,2'-BISIMIDAZOLES

Disclosed are compositions derived from 2,2′bisimidazoles building blocks and methods of making the same. The disclosed compositions are capable of withstanding temperatures up to 600° C. and substantially flame resistant.

A CONVERGENT APPROACH TO THE TOTAL SYNTHESIS OF TELMISARTAN VIA A SUZUKI CROSS-COUPLING REACTION

Methods of synthesizing the angiotensin II receptor antagonist telmisartan in high yield and purity are provided. The methods involve the coupling of two structurally distinct benzimidazole units via a Suzuki cross-coupling reaction. Methods of regioselectively synthesizing one of the benzimidazole units are also provided. 2. The method of claim 1 , wherein said step of coupling is carried out using microwave assisted heating.3. The method of claim 1 , further comprising the step of forming said potassium(1-(2′-carboxy-[1 claim 1 ,1′-biphenyl]-4-yl)-4-methyl-2-propyl-benzimidazole-6-yl) trifluoroborate byi) pre-treating potassium(4-methyl-2-propyl-benzimidazole-6-yl) trifluoroborate with potassium tert-butoxide; andii) alkylating pretreated potassium(4-methyl-2-propyl-benzimidazole-6-yl) trifluoroborate with methyl 4′-bromomethyl-biphenyl-2-carboxylate, to form said potassium(1-(2′-carboxy-[1,1′-biphenyl]-4-yl)-4-methyl-2-propyl-benzimidazole-6-yl) trifluoroborate.4. The method of claim 1 , further comprising the step of forming said 2-bromo-1-methylbenzim idazole byregioselectively brominating a 2-position of 1 -methylbenzimidazole to form 2-bromo-1-methylbenzimidazole.5. The method of further comprising the step of forming said potassium(4-methyl-2-propyl-benzimidazole-6-yl) trifluoroborate byi) performing reductive cyclization of 4-bromo-2-methyl-6-nitroaniline in the presence of n-butyraldehyde and sodium dithionite to form 6-bromo-4-methyl-2-propylbenzimidazole; andii) converting said 6-bromo-4-methyl-2-propylbenzimidazole to a trifluoroborate salt, to form said potassium(4-methyl-2-propyl-benzimidazole-6-yl) trifluoroborate.6. The method of claim 5 , wherein said step of converting is performed byreacting said 6-bromo-4-methyl-2-propylbenzimidazole with diboron pinacol ester in the presence of a catalyst to form a boronic acid pinacol ester; andconverting said boronic acid pinacol ester to said potassium(4-methyl-2-propyl-benzimidazole-6-yl) trifluoroborate.7. ...

Organic el device and display unit

An organic EL device of the disclosure includes: a first electrode and a second electrode; and an organic layer provided between the first electrode and the second electrode. The organic layer includes a light-emitting layer. The organic layer includes, between the first electrode and the light-emitting layer, a first layer that contains a polycyclic aromatic hydrocarbon compound having orientation, and a second layer that contains a larger amount of nitrogen element than the first layer.

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases). 45-. (canceled)7. (canceled)910-. (canceled)1213-. (canceled)1617-. (canceled)18. The compound of claim 3 , wherein Z is CH.2021-. (canceled)22. The compound of claim 19 , wherein W is O.23. The compound of claim 22 , wherein Ris methyl.24. The compound of claim 23 , wherein Ris phenyl claim 23 , furanyl claim 23 , thienyl claim 23 , —≡—CF claim 23 , OCF claim 23 , or OCHF claim 23 , wherein the phenyl can be optionally substituted with halogen claim 23 , CN claim 23 , C-C-alkyl claim 23 , OH claim 23 , C-Calkoxy claim 23 , formyl claim 23 , acetyl claim 23 , acetoxy claim 23 , or carboxyl claim 23 , and wherein the furanyl and the thienyl each can be optionally substituted with C-C-alkyl.25. (canceled)28. The compound of claim 27 , wherein Ris hydrogen claim 27 , halogen claim 27 , methyl claim 27 , CN claim 27 , OCH claim 27 , CF claim 27 , OCF claim 27 , OCHF claim 27 , or cyclopropyl.29. (canceled)30. The compound of claim 28 , wherein Ris hydrogen or halogen.3135-. (canceled)37. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound of claim 1 , or a pharmaceutically acceptable salt thereof.3839-. (canceled)40. A method of treating a PPARδ related disease or condition in a subject claim 1 , comprising administering to the subject in need thereof a therapeutically effective amount of one or more compounds of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , or a pharmaceutical composition comprising the compound of and a pharmaceutically acceptable excipient.41. A method of increasing or maintaining muscle mass or muscle tone in a subject claim 1 , comprising administering to the subject a therapeutically effective amount of one or more compounds of claim 1 , or a pharmaceutically acceptable ...

ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME

The present disclosure provides a compound represented by formula (I): 2. The compound of claim 1 , wherein X represents an unsubstituted (C1-C10) alkyl claim 1 , an unsubstituted (C6-C30) aryl or a (C6-C30) aryl substituted by a (C1-C10) alkyl.3. The compound of claim 1 , wherein X represents methyl claim 1 , phenyl or tolyl.5. An organic electroluminescent device claim 1 , comprising:a cathode;an anode; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'an organic layer formed between the cathode and the anode, wherein the organic layer comprises the compound according to .'}6. The organic electroluminescent device of claim 5 , wherein claim 5 , based on a total weight of the organic layer claim 5 , an amount of the compound represented by formula (I) is in a range of from about 25 wt % to about 100 wt %.7. The organic electroluminescent device of claim 5 , wherein a thickness of the organic layer is in a range of from about 1 nm to about 500 nm.8. The organic electroluminescent device of claim 5 , wherein the organic layer is an electron transport layer claim 5 , an electron injection layer claim 5 , a light-emitting layer claim 5 , a hole block layer or an electron block layer.9. The organic electroluminescent device of claim 5 , the organic layer is an electron transport or injection layer comprising n-type electrically conducting dopants.10. The organic electroluminescent device of claim 9 , wherein an amount of the n-type electrically conducting dopants is from about 20 wt % to about 75 wt % based on a total weight of the organic layer.11. The organic electroluminescent device of claim 5 , wherein the organic layer is a light-emitting layer comprising a fluorescent or phosphorescent emitter.12. The organic electroluminescent device of claim 5 , further comprising an emitting layer formed between the cathode and the anode claim 5 , wherein the emitting layer comprises a fluorescent or phosphorescent emitter and is free of the compound represented by formula ...

Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same

A novel derivative of heterocyclic compound having nitrogen atom with a structure made by bonding special groups to benzimidazole, a material for an organic electroluminescence (EL) device comprising the derivative of heterocyclic compound having nitrogen atom and an organic electroluminescence device comprising at least one organic compound layer containing a light emitting layer sandwiched between a pair of electrodes, wherein the device contains the derivative of heterocyclic compound having nitrogen atom. An organic EL device achieving elevation of luminance and of efficiency in light emission even under low driving voltage is obtainable by an employment of the derivative of heterocyclic compound having nitrogen atom for at least one layer composing organic compound layers of the EL device.

Phenylbenzimidazole derivatives

Described herein is an anticancer agent, an antiviral agent or an antimicrobial agent which contains, as an active ingredient for acting on DNA, a compound presented by the following formula (1) or its pharmacologically acceptable salt: <IMAGE> (1)

一种串联式有机发光二极管、阵列基板及显示装置

本发明公开一种串联式有机发光二极管、阵列基板及显示装置，涉及显示技术领域，为解决串联式有机发光二极管正常发光所需的驱动电压较高的问题。所述串联式有机发光二极管包括依次层叠的阳极、空穴传输层、第一发光层、第一电荷产生层、第二电荷产生层、第三电荷产生层、第四电荷产生层、第二发光层、电子传输层和阴极；第一电荷产生层为N型体异质结，第二电荷产生层与第三电荷产生层均为PN结型体异质结，第二电荷产生层中的P型有机材料的比例大于N型有机材料的比例，第三电荷产生层中的P型有机材料的比例小于N型有机材料的比例，第四电荷产生层为P型体异质结。本发明提供的串联式有机发光二极管应用于显示装置中。

N-甲基取代苯并咪唑类含氟液晶化合物及其制备方法

本发明公开了一种N‑甲基取代苯并咪唑类含氟液晶化合物及其制备方法，属于液晶材料技术领域。该化合物的结构式为 式中R代表C 5 ～C 12 的直链烷基，X代表氢、甲基或硝基。该化合物是以3‑氟‑4‑溴苯甲醛、2‑甲基‑3‑丁炔‑2‑醇、1‑碘‑4‑(烷氧基)苯、邻苯二胺类化合物、碘甲烷为原料，通过Sonogashira偶联、亲核加成、亲核取代等反应制备。本发明化合物具有大双折射率，且其制备方法步骤简单，可应用于液晶光电器件中，以提高其响应速度。

2-芳基苯并咪唑的合成方法

本发明公开了一种从芳基卤甲烷和1,2-二氨基芳烃合成2-芳基苯并咪唑的方法。2-芳基苯并咪唑类化合物具有广泛的生物活性和药用价值。芳基卤甲烷容易从甲基芳烃卤化得到，廉价易得。在空气下，亚铜盐催化芳基卤甲烷和1,2-二氨基芳烃反应得到2-芳基苯并咪唑类化合物。该方法原料较易得、成本较低、官能团耐受性广，适合工业生产。

Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same

본 발명은 벤즈이미다졸에 특정한 기가 결합된 구조를 갖는 신규한 질소 함유 헤테로환 유도체, 질소 함유 헤테로환 유도체로 이루어지는 유기 전기발광(EL) 소자용 재료, 및 한 쌍의 전극 사이에 협지된 발광층을 포함하는 1층 이상의 유기 화합물층을 갖는 유기 EL 소자로서, 상기 질소 함유 헤테로환 유도체를 상기 유기 화합물층 중 1층 이상에 함유하는 유기 EL 소자에 관한 것으로, 유기 EL 소자의 구성 성분으로서 유용한 신규한 질소 함유 헤테로환 유도체를 제공하고, 이 질소 함유 헤테로환 유도체를 유기 화합물층 중 1층 이상에 이용함으로써, 저전압이면서 발광 휘도 및 발광 효율이 높은 유기 EL 소자를 제공한다. The present invention provides a novel nitrogen-containing heterocyclic derivative having a structure in which a specific group is bonded to benzimidazole, an organic electroluminescent (EL) device material comprising a nitrogen-containing heterocyclic derivative, and a light emitting layer sandwiched between a pair of electrodes. An organic EL device having at least one organic compound layer, comprising an organic EL device containing the nitrogen-containing heterocyclic derivative in at least one layer of the organic compound layer, wherein the novel nitrogen-containing compound is useful as a constituent of the organic EL device. By providing a heterocyclic derivative and using this nitrogen-containing heterocyclic derivative in at least one layer of the organic compound layer, an organic EL device having a low voltage and high luminescence brightness and luminescence efficiency is provided.

신규한 질소 함유 헤테로환 유도체 및 이를 이용한 유기 전기발광 소자

본 발명은 벤즈이미다졸에 특정한 기가 결합된 구조를 갖는 신규한 질소 함유 헤테로환 유도체, 질소 함유 헤테로환 유도체로 이루어지는 유기 전기발광(EL) 소자용 재료, 및 한 쌍의 전극 사이에 협지된 발광층을 포함하는 1층 이상의 유기 화합물층을 갖는 유기 EL 소자로서, 상기 질소 함유 헤테로환 유도체를 상기 유기 화합물층 중 1층 이상에 함유하는 유기 EL 소자에 관한 것으로, 유기 EL 소자의 구성 성분으로서 유용한 신규한 질소 함유 헤테로환 유도체를 제공하고, 이 질소 함유 헤테로환 유도체를 유기 화합물층 중 1층 이상에 이용함으로써, 저전압이면서 발광 휘도 및 발광 효율이 높은 유기 EL 소자를 제공한다.

The synthetic method of 2-aryl benzoglyoxaline

本发明公开了一种从芳基卤甲烷和1,2-二氨基芳烃合成2-芳基苯并咪唑的方法。2-芳基苯并咪唑类化合物具有广泛的生物活性和药用价值。芳基卤甲烷容易从甲基芳烃卤化得到，廉价易得。在空气下，亚铜盐催化芳基卤甲烷和1,2-二氨基芳烃反应得到2-芳基苯并咪唑类化合物。该方法原料较易得、成本较低、官能团耐受性广，适合工业生产。

Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same

본 발명은 벤즈이미다졸에 특정한 기가 결합된 구조를 갖는 신규한 질소 함유 헤테로환 유도체, 질소 함유 헤테로환 유도체로 이루어지는 유기 전기발광(EL) 소자용 재료, 및 한 쌍의 전극 사이에 협지된 발광층을 포함하는 1층 이상의 유기 화합물층을 갖는 유기 EL 소자로서, 상기 질소 함유 헤테로환 유도체를 상기 유기 화합물층 중 1층 이상에 함유하는 유기 EL 소자에 관한 것으로, 유기 EL 소자의 구성 성분으로서 유용한 신규한 질소 함유 헤테로환 유도체를 제공하고, 이 질소 함유 헤테로환 유도체를 유기 화합물층 중 1층 이상에 이용함으로써, 저전압이면서 발광 휘도 및 발광 효율이 높은 유기 EL 소자를 제공한다. The present invention provides a novel nitrogen-containing heterocyclic derivative having a structure in which a specific group is bonded to benzimidazole, an organic electroluminescent (EL) device material comprising a nitrogen-containing heterocyclic derivative, and a light emitting layer sandwiched between a pair of electrodes. An organic EL device having at least one organic compound layer, comprising an organic EL device containing the nitrogen-containing heterocyclic derivative in at least one layer of the organic compound layer, wherein the novel nitrogen-containing compound is useful as a constituent of the organic EL device. By providing a heterocyclic derivative and using this nitrogen-containing heterocyclic derivative in at least one layer of the organic compound layer, an organic EL device having a low voltage and high luminescence brightness and luminescence efficiency is provided.

Benzimidazoles compound and application thereof

本发明提供了一类苯并咪唑类化合物及其应用，所述化合物具有通式(I)的结构。该通式化合物由对2‑(3,4,5‑三羟基苯基)‑1H‑苯并咪唑的1位和/或6位进行化合物修饰(即分别引入R 1 和R 2 )而获得。本发明的苯并咪唑类化合物能模拟Bim,在体外和细胞内竞争性结合和拮抗Bcl‑2/Mcl‑1蛋白，从而诱导细胞凋亡，是一类活性很高的凋亡诱导剂和抗肿瘤化合物。

Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same

본 발명은 벤즈이미다졸에 특정한 기가 결합된 구조를 갖는 신규한 질소 함유 헤테로환 유도체, 질소 함유 헤테로환 유도체로 이루어지는 유기 전기발광(EL) 소자용 재료, 및 한 쌍의 전극 사이에 협지된 발광층을 포함하는 1층 이상의 유기 화합물층을 갖는 유기 EL 소자로서, 상기 질소 함유 헤테로환 유도체를 상기 유기 화합물층 중 1층 이상에 함유하는 유기 EL 소자에 관한 것으로, 유기 EL 소자의 구성 성분으로서 유용한 신규한 질소 함유 헤테로환 유도체를 제공하고, 이 질소 함유 헤테로환 유도체를 유기 화합물층 중 1층 이상에 이용함으로써, 저전압이면서 발광 휘도 및 발광 효율이 높은 유기 EL 소자를 제공한다.

Tandem-type organic light-emitting diode, array substrate, and display device

本发明公开一种串联式有机发光二极管、阵列基板及显示装置，涉及显示技术领域，为解决串联式有机发光二极管正常发光所需的驱动电压较高的问题。所述串联式有机发光二极管包括依次层叠的阳极、空穴传输层、第一发光层、第一电荷产生层、第二电荷产生层、第三电荷产生层、第四电荷产生层、第二发光层、电子传输层和阴极；第一电荷产生层为N型体异质结，第二电荷产生层与第三电荷产生层均为PN结型体异质结，第二电荷产生层中的P型有机材料的比例大于N型有机材料的比例，第三电荷产生层中的P型有机材料的比例小于N型有机材料的比例，第四电荷产生层为P型体异质结。本发明提供的串联式有机发光二极管应用于显示装置中。

Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same

A novel nitrogen-containing heterocycle derivative having a structure obtained by bonding a specific group to benzimidazole; a material for an organic electroluminescent (EL) element comprising the nitrogen-containing heterocycle derivative; and an organic EL element having one pair of electrodes and, sandwiched between them, at least one organic compound layer including a luminous layer, characterized in that the at least one organic compound layer comprises the above nitrogen-containing heterocycle derivative. The novel nitrogen-containing heterocycle derivative is useful as a component of an organic EL element, and the organic EL element is capable of exhibiting high luminous brightness and high luminous efficiency with a low electron voltage.

Nitogen-contained heterocycle derivant and use the organic electroluminescent device of this derivative

一种具有通过键合特定基团至苯并咪唑所得结构的、新的含氮杂环衍生物；包含含氮杂环衍生物的用于有机电致发光(EL)元件的材料；及具有一对电极和至少一层夹在它们之间的有机化合物层的有机EL元件，该有机化合物层包括发光层，其特征在于至少一层有机化合物层包含上述含氮杂环衍生物。这类新的含氮杂环衍生物用作有机EL元件组分，且该有机EL元件在低电压下能表现出高发光亮度和高发光效率。

Bipolar hosts for light emitting devices

Some embodiments provide a compound represented by Formula 1: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are independently H, C 1 -C 3 alkyl, or C 1-3 perfluoroalkyl; HT is optionally substituted carbazoyl, optionally substituted phenylcarbazolyl, optionally substituted (phenylcarbazolyl)phenyl, optionally substituted phenylnaphthylamine, or optionally substituted diphenylamine; and ET optionally substituted benzimidazol-2-yl, optionally substituted benzothiazol-2-yl, optionally substituted benzoxazol-2-yl, optionally substituted 3,3′-bipyridin-5-yl, optionally substituted quinolin-8-yl, optionally substituted quinolin-5-yl, or optionally substituted quinoxalin-5-yl. Other embodiments provide an organic light-emitting diode device comprising a compound of Formula 1.

NITROGEN-CONTAINING HETEROCYCLUS DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT HAVING THIS USE

Metal-complex compound ands organic electroluminescence device using the compound

A metal-complex compound which comprises a tridentate chelate ligand having a specified partial structure. An organic electroluminescence device which comprises at least one organic thin film layer sandwiched between a pair of electrode consisting of an anode and a cathode, wherein the organic thin film layer comprises the metal-complex compound, which emits light by applying an electric voltage between the pair of electrode. The present invention provides an organic EL device which emits blue light with high purity and of short wavelength with an enhanced efficiency of light emission.

Metal-complex compound and organic electroluminescence device using the compound

A metal-complex compound which comprises a tridentate chelate ligand having a specified partial structure. An organic electroluminescence device which comprises at least one organic thin film layer sandwiched between a pair of electrode consisting of an anode and a cathode, wherein the organic thin film layer comprises the metal-complex compound, which emits light by applying an electric voltage between the pair of electrode. The present invention provides an organic EL device which emits blue light with high purity and of short wavelength with an enhanced efficiency of light emission.

Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same

A novel derivative of heterocyclic compound having nitrogen atom with a structure made by bonding special groups to benzimidazole, a material for an organic electroluminescence (EL) device comprising the derivative of heterocyclic compound having nitrogen atom and an organic electroluminescence device comprising at least one organic compound layer containing a light emitting layer sandwiched between a pair of electrodes, wherein the device contains the derivative of heterocyclic compound having nitrogen atom. An organic EL device achieving elevation of luminance and of efficiency in light emission even under low driving voltage is obtainable by an employment of the derivative of heterocyclic compound having nitrogen atom for at least one layer composing organic compound layers of the EL device.

Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same

A novel derivative of heterocyclic compound having nitrogen atom with a structure made by bonding special groups to benzimidazole, a material for an organic electroluminescence (EL) device comprising the derivative of heterocyclic compound having nitrogen atom and an organic electroluminescence device comprising at least one organic compound layer containing a light emitting layer sandwiched between a pair of electrodes, wherein the device contains the derivative of heterocyclic compound having nitrogen atom. An organic EL device achieving elevation of luminance and of efficiency in light emission even under low driving voltage is obtainable by an employment of the derivative of heterocyclic compound having nitrogen atom for at least one layer composing organic compound layers of the EL device.

Nitrogen containing heterocycle derivative and organic electroluminescent element using the same

A novel derivative of heterocyclic compound having nitrogen atom with a structure made by bonding special groups to benzimidazole, a material for an organic electroluminescence (EL) device comprising the derivative of heterocyclic compound having nitrogen atom and an organic electroluminescence device comprising at least one organic compound layer containing a light emitting layer sandwiched between a pair of electrodes, wherein the device contains the derivative of heterocyclic compound having nitrogen atom. An organic EL device achieving elevation of luminance and of efficiency in light emission even under low driving voltage is obtainable by an employment of the derivative of heterocyclic compound having nitrogen atom for at least one layer composing organic compound layers of the EL device.

Benzimidazolone antiviral agents

The present invention concerns antiviral compounds, their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazolone derivatives for the treatment of respiratory syncytial virus infection.

Preparation method of telmisartan

本发明涉及一种替米沙坦的制备方法。本发明的制备方法以3‑甲基‑4‑正丁酰胺基苯甲酸为原料，经氰化、硝化、还原、合环等反应制备了中间体(1)，中间体(1)与4’‑溴甲基联苯‑2‑甲酸甲酯缩合生成中间体(2)，中间体(2)与N‑甲基邻苯二胺缩合制备中间体(3)，最后水解制备了替米沙坦。本发明开发了一条替米沙坦新的制备方法，本方法采用的原料3‑甲基‑4‑正丁酰胺基苯甲酸易得，价格便宜；反应条件温和，容易操作，收率高，氰基化反应避免了有毒的氰化物的使用，对环境污染小，适合工业化生产。

Manufacture of dibenzazolyl compound

Electron lens assembly for electron beam melting or evaporation systems

Compounds, compositions and methods for treatment of hepatitis C

Heterocyclic substituted carboxamides are useful in prophylaxis and treatment of hepatitis C virus infections.

Polymorphs of telmisartan

The invention relates to polymorphs of 4′-[2-n-propyl-4-methyl-6-(1-methylbenzimid-azol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), particularly polymorphic form B, mixtures of the polymorphs, processes for preparing telmisartan containing form B and the use thereof for preparing a pharmaceutical composition.

Crystalline form of telmisartan sodium

The invention relates to a crystalline sodium salt of 4′-[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), processes for preparing it and the use thereof for preparing a pharmaceutical composition.

Processes of preparing highly pure telmisartan form A, suitable for pharmaceutical compositions

Processes are disclosed for preparing Telmisartan form A, which is free-flowing and which does not contain electrostatic charge and is thus industrially process-able. The free-flowing Telmisartan form A is prepared by crystallization from a polar organic solvent e.g., DMSO, DMF, DMA, NMP, or water and is suitable for use in pharmaceutical compositions. A process is also disclosed for preparing highly-pure Telmisartan form A by precipitation from aqueous solutions.

Amorphous and polymorphic forms of telmisartan sodium

Provided is the amorphous form of telmisartan sodium and the preparation thereof. Also provided are the telmisartan sodium polymorph crystal Forms 0 to XIII and XV to XX and preparations thereof. Also provided are pharmaceutical composition of amorphous and polymorphic forms of telmisartan sodium or mixtures thereof, and methods of treatment of a mammal in need thereof.

Crystalline form of telmisartan sodium

The invention relates to a crystalline sodium salt of 4′-[2-n-propyl-4-methyl-6-(1-methyl-benzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), processes for preparing it and the use thereof for preparing a pharmaceutical composition.

Crystalline Form of Telmisartan Sodium

The invention relates to a crystalline sodium salt of 4′-[2-n-propyl-4-methyl-6-(1-methyl-benzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), processes for preparing it and the use thereof for preparing a pharmaceutical composition.

Process for preparing and purifying 1,7′-dimethyl-2′-propyl-2,5′-bi-1H-benzimidazole

Disclosed is a process which can be used on an industrial scale for preparing and purifying 1,7′-dimethyl-2′-propyl-2,5′-bi-1H-benzimidazole in which the crude product is subjected to charcoal treatment.

Nitrogenous heterocycle derivative and organic electroluminescent element employing the same

본 발명에 따라 낮은 전압에 있어서도 높은 발광 효율이 가능한 유기 EL 소자를 실현할 수 있는 유기 EL 소자용 재료가 제공된다. 하기 화학식 1a 또는 2a로 표시되는 질소함유 헤테로환 유도체가 제공된다: According to the present invention, there is provided an organic EL device material capable of realizing an organic EL device capable of high luminous efficiency even at a low voltage. There is provided a nitrogen-containing heterocyclic derivative represented by Formula 1a or 2a: 화학식 1a Formula 1a 화학식 2a Formula 2a 상기 식에서, Where R 1a 내지 R 5a 각각은 치환기를 나타내며, Each of R 1a to R 5a represents a substituent, Ar 1a 내지 Ar 3a 각각은 단일 결합 또는 2가의 연결기를 나타내며, Each of Ar 1a to Ar 3a represents a single bond or a divalent linking group, HAr은 하기 화학식 3a 또는 4a로 표시되는 기를 나타낸다: HAr represents a group represented by formula 3a or 4a: 화학식 3a Formula 3a 화학식 4a 4a (상기 식에서, R 6a 내지 R 10a 는 각각 치환기를 나타낸다.) (Wherein R 6a to R 10a each represent a substituent)

Method of producing telmisartan

FIELD: chemistry. SUBSTANCE: method is realised by reacting 2-n-propyl-4-methyl-6-(1'-methylbenzimidazol-2'-yl)benzimidazole with a compound of formula , in which Z denotes a leaving group. The compound obtained this way undergoes suitable treatment if necessary. The cyano group of the obtained 2-cyano-4'-[2"-n-propyl-4"-methyl-6"-(1'"-methylbenzimidazol-2'"-yl)benzimidazol-1"-ylmethyl]biphenyl of formula is then converted to an acid functional group through hydrolysis at temperature ranging from 140°C to 200°C in the presence of a base in a system of high-boiling solvents, and the obtained telmisartan is converted to a hydrochloride during processing if necessary. EFFECT: easy processing, treatment and extraction of telmisartan. 12 cl, 7 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 430 092 (13) C2 (51) МПК C07D 235/20 C07D 403/04 (2006.01) (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21)(22) Заявка: 2005133479/04, 26.03.2004 (24) Дата начала отсчета срока действия патента: 26.03.2004 C 2 (56) Список документов, цитированных в отчете о поиске: RU 2053229 С1, 27.01.1996. Ries U.J. et all "6-Substituted Benzimidazoles as New Nonpeptide Angiotensin II Receptor Antagonists: Synthesis, Biological Activity and StructureActivity Relationships" JOURNAL OF MEDICINAL CHEMISTRY, Vol.36, №25, 1993, 4040-4051. C 2 2 4 3 0 0 9 2 (45) Опубликовано: 27.09.2011 Бюл. № 27 2 4 3 0 0 9 2 R U (73) Патентообладатель(и): БЁРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГМБХ (DE) (43) Дата публикации заявки: 27.07.2006 Бюл. № 21 R U Приоритет(ы): (30) Конвенционный приоритет: 31.03.2003 DE 10314702.0 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 31.10.2005 (86) Заявка PCT: EP 2004/003217 (26.03.2004) (87) Публикация заявки РСТ: WO 2004/087676 (14.10.2004) Адрес для переписки: 101000, Москва, М. Златоустинский пер., 10, кв. 15, "ЕВРОМАРКПАТ", пат.пов. И.А. Веселицкой, ...

Telmisartan methanesulfonate and pharmaceutical composition comprising the same

본 발명은 텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물에 관한 것이다. 본 발명에 따른 텔미사르탄 메탄술폰산염은 안정성, 용해도 및 고체흐름성이 우수할 뿐만 아니라, 간단한 직접압축법에 의해 용출율이 우수한 정제를 제조할 수 있어 약제학적 조성물에 효과적으로 사용될 수 있다.

COSMETIC AND DERMATOLOGICAL PREPARATIONS CONTAINING PHENYLENE-1,4-BISBENZIMIDIAZOLESULFONIC ACIDS

Organic electroluminescence device and polycyclic compound for organic electroluminescence device

일 실시예의 유기 전계 발광 소자는 제1 전극, 제1 전극과 마주하는 제2 전극, 및 제1 전극 및 상기 제2 전극 사이에 배치된 복수의 유기층들을 포함하고, 복수의 유기층들 중 적어도 하나의 유기층은 단일 결합으로 연결된 2개의 방향족 6원고리들 및 상기 2개의 방향족 6원고리들에 치환된 복수의 벤즈이미다졸기들을 포함하는 다환 화합물을 포함하며, 2개의 방향족 6원고리들 각각은 고리형성 원자로 탄소 원자 또는 질소 원자를 포함하여 고효율 및 장수명을 나타낼 수 있다.

Fluorescence identifying fluorinion sensor and preparation and application thereof

本发明提供了一种高选择性荧光识别氟离子的传感器，属于阴离子检测领域。该传感器是以对苯二甲酸和邻苯二胺为底物，多聚磷酸为催化剂，磷酸为脱水剂，在氮气保护下，于160~200℃下搅拌反应5~6h，产物倾入蒸馏水中，用碱液调节pH值至8~9，抽滤，水洗，干燥，重结晶，得到土黄色目标产物。实验表明，在传感器分子的DMSO溶液中；分别加入F - 、Cl - 、Br - 、I - 、AcO - 、H 2 PO 4 - 、HSO 4 - 、ClO 4 - 和SCN - 的DMSO溶液，发现只有F - 的加入使得溶液在紫外灯下发出显著的蓝色荧光。因此，该传感器可用于F - 的荧光快速检测，而且这一识别过程不受其它阴离子的干扰。为了便于实际应用，本发明还制作了基于该传感器的氟离子检测试纸。

New Benzimidazoles and process for their preparation

1,174,493. Benzimidazoles. MFRS. J. R. BOTTU. 9 May, 1968 [10 May, 1967; 18 July, 1967], Nos. 21804/67 and 32933/67. Heading C2C. Novel compounds of the formula (wherein R is H, halogen, CF 3 , C 1-4 alkyl or C 1-4 alkoxy; and R<SP>1</SP> and R<SP>2</SP> are each halogen, CF 3 , C 1-4 alkyl, C 1-4 alkoxy, OH, C 1-4 aminoalkoxy, mono- or di-alkyl-amino-alkoxy with 1-4 C atoms in each alkyl residue, or CO 2 H) and acid-addition salts thereof are prepared by oxidizing compounds of the formula (e.g. by heating with nitrobenzene or m-dinitrobenzene) which are in turn prepared by condensing the appropriately substituted N- phenyl - o - phenylenediamine with the appropriately substituted benzaldehyde. The benzimidazoles of the invention are antiinflammatory and analgesic agents, and they may be made up into pharmaceutical compositions with suitable carriers.

Patent FR7408M

2-(fluorophenyl) benzimidazoles - as antiinflammatory and analgesic agents

Antiinflammatory, analgesic, compsn. comprises as active ingredient 2-(3-fluorophenyl)benzimidazole, 2-(4-fluorophenyl)-benzimidazole or their pharmaceutically acceptable acid addition salts. The cpds. are of low toxicity and suitable for oral or rectal administration.

2-(4'-aminophenyl)-5-amino-benzimidazole prepn. - from para-nitrobenzoic acid by condensn. with aniline,di-nitration, redn. and cyclo-dehydration(BE130776)

2-(4'-Amino-phenyl)-5-amino-benzimidazole (A) is prepd. by condensing p-nitrobenzoic acid (I) with aniline, di-nitrating the N-(4'-nitrobenzoyl)-aniline (II) obtd. to form N-(4'-nitrobenzoyl)-2,4-dinitroaniline (III), reducing (III) to the corresponding triamine (IV) and cyclo-dehydrating (IV) to (A). Process also relates to prepn. of the 6-Cl-or 6-alkyl-deriv. of (A). (A) is an inter. in the prepn. of polyazo dyes. (A) can be prepd. economically, in high yields, from readily available materials.

Method for sensitizing photographic emulsions to silver halide

Process for the preparation of diimidazole derivatives

Process for manufacturing benzimidazoles substituted in position 2

Improvements made to products that destroy animals and noxious plants and to disinfectants

Patent FR2373533B1

New polyazoles, their preparation process and their use

New higher alkyl-substituted oligo-benzimidazole derivatives, useful as nucleic acid transfection agents detectable by fluorescence, e.g. for use in gene therapy

Oligo-benzimidazole derivatives (I), containing at least one higher alkyl substituent, are new. Oligo-benzimidazole derivatives of formula (I) and their salts with metals, nitrogen-containing bases or acids are new. R = H, COOH, alkoxycarbonyl, carbamoyl, alkylcarbamoyl, piperazinyl (optionally 4-substituted by 1-4C alkyl) or imidazolyl, n = 2-5; R' = OR3, SR3, NHR3, OCONHR3, NR4R5 or OCONR4R5; R3 - R5 = 12-22C alkyl; with the proviso the compound (I; R = 4-methylpiperazinyl; R' = dodecyloxy; n = 2) (I') is excluded. Independent claims are also included: (1) a composition comprising (I) or (I') and a nucleic acid; and (2) a method of transferring nucleic acids into cells, involving contacting the nucleic acid with (I) or (I') (optionally together with adjuvant(s) and/or carrier(s)) then contacting the obtained complex with the cells.

Process for the preparation of azole compounds

Process for the production of 2-substituted benzimidazoles

Method for sensitizing photographic emulsions

Process for the preparation of diimidazole derivatives

Cosmetic and dermatological preparations, containing phenylene-1,4-bisbenzimidazole sulfonic acids

A process for the preparation of telmisartan

A process for the preparation of telmisartan (I) and novel intermediates useful for its synthesis.

Process for the preparation of phenylene-bis-benzimidazol-tetrasulfonic acid disodium salt

A reaction time of 10-15 hours is used in a method for the production of phenylene-bis-benzimidazole-tetrasulfonic acid di-sodium salt (I) by reacting o-phenylenediamine with terephthalic acid and chlorosulfonic acid in the presence of a strong acid.

Organic electric-field light-emitting element, light-emitting material for organic electric-field light-emitting element, and light-emitting device, display device, and illumination device using same element

하기 일반식으로 나타내는 화합물을 사용한 유기 전계 발광 소자는 암청색 발광이고, 휘도 변조시의 색도 변화가 작다 (n1 은 0 ∼ 8 의 정수；R 1 은 각각 독립적으로 피렌 골격의 수소 원자로 치환하는 치환기；X 는 CR a R b (R a , R b 는 각각 독립적으로 수소 원자 또는 치환기), O, S, SiR d R e (R d , R e 는 각각 독립적으로 수소 원자 또는 치환기) 중 어느 것；A 1 ∼ A 4 는 각각 독립적으로 CR f (R f 는 수소 원자 또는 치환기를 나타내고, 이웃하는 2 개의 R f 는 공동하여 포화 또는 불포화 고리를 형성하고 있어도 되지만, 2 개 이상의 R f 가 공동하여 형성하는 고리는 2 개 이하) 또는 N 중 어느 것을 나타낸다.). The organic electroluminescent device using the compound represented by the following general formula has a dark blue light emission and a small change in chromaticity at the time of luminance modulation (n1 is an integer of 0 ~ 8; R 1 is a substituent replacing the hydrogen atom of a pyrene skeleton, each independently; X is CR a R b (R a, R b is hydrogen atom or a substituent, each independently), O, S, SiR d R e which of (R d, R e is hydrogen atom or a substituent, each independently); a 1 ~ a 4 are each independently CR f (R f is a hydrogen atom or a substituent, and two R neighboring f may jointly form a saturated or unsaturated ring, but two or more rings formed by two or more R f are jointly formed) or N).

BENZIMIDAZOLES AND PROCEDURES FOR THEIR PREPARATION

Butynoic amide derivative, and preparation process, pharmaceutical composition and uses thereof

本发明公开了式I所示的丁炔酰胺衍生物，其可药用盐，及其制备方法，含有一个或多个这化合物的组合物，和该类化合物在治疗与蛋白激酶有关的疾病如免疫失调和肿瘤疾病方面的用途。

N- methyl substituted benzimidazole liquid-crystal compounds containing acetylene bond and preparation method thereof

本发明公开了一种含炔键的N‑甲基取代苯并咪唑液晶化合物及其制备方法，属于材料技术领域。该液晶化合物的结构式为 式中R代表C 5 ～C 12 的直链烷基，X代表氢、甲基或硝基。该化合物以对溴苯甲醛、2‑甲基‑3‑丁炔‑2‑醇、1‑碘‑4‑(烷氧基)苯、邻苯二胺类化合物、碘甲烷为原料，通过Sonogashira偶联、亲核加成、关环等反应制备。本发明液晶化合物具有大的双折射率，且其制备方法步骤简单，可用于液晶光电器件中，以提高其响应速度。

Novel PPAR agonists, pharmaceutical compositions and uses thereof

The present invention provides novel compounds and pharmaceutical compositions thereof, which at least partially activate PPARγ and may further inhibit the activity of the AT1 receptor. The novel compounds include certain substituted benzimidazole compounds of Formulae I and II, infra. The invention also provides methods of treating inflammatory and metabolic disorders and methods for screening compounds for the capability to treat or prevent an inflammatory or metabolic disorder.

2'-halobiphenyl-4-yl intermediates in the synthesis of angiotensin ii antagonists

描述了用于获得2’-卤代-4-甲基联苯的方法，其包括将4-卤代甲苯与1，2-二卤代苯在元素金属例如镁、锂或锌的存在下反应，其中使用相对于1，2-二卤代苯而言0～0.9摩尔、特别是0～0.2摩尔过量的4-卤代甲苯，并且通过元素卤素淬灭所产生的有机金属中间体。此外，也描述了如下方法：将所产生的2’-卤代-4-甲基联苯与2-(1-丙基)-4-甲基-6-(1’-甲基苯并咪唑-2-基)苯并咪唑偶联，得到3’-(2’-卤代-联苯-4-基甲基)-1，7’-二甲基-2’-丙基-1H，3’H-[2，5’]联苯并咪唑基，其可以进一步被转化为有机金属化合物，且将所述有机金属化合物与甲酸衍生物例如N，N-二甲基甲酰胺、烷基甲酸酯或二氧化碳进一步反应以获得替米沙坦。还描述了使用在线分析监控前述反应，用于制备药物组合物和/或剂型的方法，或在制备药物中的用途。

Patent FR2332273B2

A Photographic Material containing a Colour Coupler

1,184,489. Benzimidazoles. AGFA-GEVAERT A.G. 24 Nov., 1967 [25 Nov., 1966], No. 53521/67. Heading C2C. [Also in Division G2] Benzimidazoles of formula (in which R 1 is C 1-5 alkyl, cycloalkyl, alkoxyalkyl or hydroxyalkyl, R 2 is H, halogen, tert. amino or C 1-18 alkyl or alkoxy, R 3 is optionally substituted phenyl, naphthyl or quasi-aromatic heterocyclic, and R 4 is sulpho, aminosulphonyl, organosulphonyl or optionally esterified carboxyl), are prepared by reacting an aminophenyl-benzimidazole with an aroylacetic ester. In an example, Na-4-chloro-3-nitrobenzene sulphonate is refluxed with n-butylamine and NaHCO 3 to form 3 - nitro - 4- butylaminobenzene sulphonic acid which is reduced by Raney nickel to 3-amino-4-butylaminobenzene sulphonic acid, which is heated with 4-nitrobenzoylchloride in pyridine to form 2 - (4<SP>1</SP> - nitrophenyl) - 3 - butyl benzimidazole - 6- sulphonic acid which is reduced to 2-(4<SP>1</SP>-aminophenyl) 3 - butylbenzimidazole - 6 - sulphonic acid which is heated with p-cetyloxy-benzoylacetic ester in the presence of pyridine and triethylamine to form a benzimidazole in which R 1 is C 4 H 9 , R 2 is H, R 3 is p-C 6 H 4 -O-C 16 H 33 and R 4 is -SO 3 H.

Unsymetric diamine monomer having trifluoromethyl and benzimidazol ring

본 발명은 트리플루오로메틸기 및 벤즈이미다졸 고리를 갖는 비대칭 구조의 다이아민 화합물에 관한 것으로, 하기 화학식 1의 화합물이며, 트리플루오로메틸기 및 벤즈이미다졸 고리를 갖는 비대칭 구조의 다이아민 화합물을 단량체로 이용하여 제조한 화학식 6의 방향족 폴리이미드는 강직한 구조로서 강인성을 나타내면서도, 최종 중합체 상태에서의 용해도가 충분하여 가공성이 우수하고, 낮은 굴절율을 가지며, 구리 등의 금속을 포함한 기질에 대한 접착력이 우수하여 전기 및 전자용, 광학용, 분리막용 기계에 사용될 수 있는 효과가 있다. The present invention relates to a diamine compound having an asymmetric structure having a trifluoromethyl group and a benzimidazole ring, which is a compound represented by the following formula (1), and has a monomer having a diamine compound having an asymmetric structure having a trifluoromethyl group and a benzimidazole ring. The aromatic polyimide of formula (6) prepared by using is a rigid structure, exhibits toughness, yet has sufficient solubility in the final polymer state, and has excellent processability, low refractive index, and adhesion to a substrate including a metal such as copper. This is excellent and there is an effect that can be used in electrical and electronic, optical, separator machine. [화학식 1] [Formula 1] [화학식 6] [Formula 6] 트리플루오로메틸기, 벤즈이미다졸 고리, 비대칭 구조, 다이아민 단량체, 방 향족 폴리이미드 Trifluoromethyl group, benzimidazole ring, asymmetric structure, diamine monomer, aromatic polyimide

Medicaments contg 2-phenyl-benzimidazoles

Medicaments contg. 2-phenyl-benzimidazoles. Compns. useful as analgesics, anti inflammatory, hypnotic, and antispasmodic agents, contg. compds. (I) or their salts. where R is H, alkyl, acyl, or CH2NR1R2; n is 1,2 or 3, R1 and R2 are alkyl or NR1R2 is opt. satd. heterocyclic ring; R' is H, OH Oalkyl; and X is H, Cl, F, alkyl, OH or Oalkyl. Compds. (I) are prepd. by standard methods for prepg. benzimidazoles or by acyln. or aminoalkyln. of (I R=H). Compns. are administered orally or rectally.

1,2-di(hetero)arylbenzimidazole derivatives, their preparation and their use as prostacyclin (pgi2) mimetics

Die Erfindung betrifft Benzimidazolderivate der Formel (I), worin R?1 und R2¿ Heteroaryl oder Phenyl, das gegebenenfalls ein- oder zweifach durch Halogen, eine geradkettige oder verzweigte Alkylgruppe mit 1-6 C-Atomen, Perfluoralkyl mit 1-4 C-Atomen, Alkoxy mit 1-6 C-Atomen, Perfluoralkoxy mit 1-4 C-Atomen, Carboxyl, geradkettiges oder verzweigtes Alkoxycarbonyl mit 1-6 C-Atomen im geradkettigen oder verzweigten Alkylteil, den Rest CONHR6, geradkettiges oder verzweigtes Alkylcarbonyl mit 1-6 C-Atomen, Nitro, Amino, den Rest NHCOR6 oder den Rest NHSO¿2R?7 substituiert sein kann, R?3 und R4¿ Wasserstoff, Halogen, eine geradkettige oder verzweigte Alkylgruppe mit 1-6 C-Atomen, Perfluoralkyl mit 1-4 C-Atomen, Alkoxy mit 1-6 C-Atomen, Perfluoralkoxy mit 1-4 C-Atomen, Carboxyl, geradkettiges oder verzweigtes Alkoxycarbonyl mit 1-6 C-Atomen im geradkettigen oder verzweigten Alkylteil, den Rest CONHR6, geradkettiges oder verzweigtes Alkylcarbonyl mit 1-6 C-Atomen, Nitro, Amino, den Rest NHCOR6 oder den Rest NHSO¿2R?7, A eine Direktbindung, geradkettiges oder verzweigtes Alkylen mit 1-8 C-Atomen, geradkettiges oder verzweigtes Alkenylen mit 2-8 C-Atomen, geradkettiges oder verzweigtes Alkinylen mit 2-8 C-Atomen, oder die Reste (a), (b) oder (c), in denen n = 1-4 sein kann, wobei eine der Methylengruppen in den Alkylen-, Alkenylen- oder Alkinylen- oder den Alkylarylenresten durch Sauerstoff oder Schwefel substituiert sein kann, oder zwei Methylengruppen durch Sauerstoff oder/und Schwefel substituiert sein können, wenn die Heteroatome durch mindestens zwei C-Atome getrennt sind, R5 Carboxyl, SO¿3?H, PO3H2 oder Tetrazolyl bedeuten, deren Salze mit physiologisch verträglichen Basen, deren Additionsverbindungen mit physiologisch verträglichen Säuren, α-, β- oder η-Cyclodextrinclathrate sowie die mit Liposomen verkapselten Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel. Die Verbindungen stellen wertvolle Hilfsmittel zur Therapie von Erkrankungen, ...

Dyes of the benzimidazole series

Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same

一种具有通过键合特定基团至苯并咪唑所得结构的、新的含氮杂环衍生物；包含含氮杂环衍生物的用于有机电致发光(EL)元件的材料；及具有一对电极和至少一层夹在它们之间的有机化合物层的有机EL元件，该有机化合物层包括发光层，其特征在于至少一层有机化合物层包含上述含氮杂环衍生物。这类新的含氮杂环衍生物用作有机EL元件组分，且该有机EL元件在低电压下能表现出高发光亮度和高发光效率。

Nitrogenous heterocyclic derivative and organic electroluminescence device making use of the same

本发明提供了一种具有特定结构的含氮杂环衍生物以及一种有机电致发光元件，所述有机电致发光元件中在阴极和阳极间挟持有至少含有发光层的由一层或多层组成的有机薄膜层，该有机薄膜层的至少一层中单独或者作为混合物的成分含有上述含氮杂环衍生物。由此可以提供低电压下的发光亮度和发光效率也高的有机电致发光元件以及实现这种有机电致发光元件的含氮杂环衍生物。

Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same

A novel derivative of heterocyclic compound having nitrogen atom with a structure made by bonding special groups to benzimidazole, a material for an organic electroluminescence (EL) device comprising the derivative of heterocyclic compound having nitrogen atom and an organic electroluminescence device comprising at least one organic compound layer containing a light emitting layer sandwiched between a pair of electrodes, wherein the device contains the derivative of heterocyclic compound having nitrogen atom. An organic EL device achieving elevation of luminance and of efficiency in light emission even under low driving voltage is obtainable by an employment of the derivative of heterocyclic compound having nitrogen atom for at least one layer composing organic compound layers of the EL device.

4,5,6,7-tetrahydrobenzimidazoles

Corrosion inhibitors and preservatives of the following formula ##SPC1## Wherein R 1 is hydrogen; R 2 is selected from the group which consists of hydrogen, the diacetoxypropionic acid methyl ester and the diacetoxypropionic acid dialkylaminoethylamide with 1 to 4 carbon atoms in the alkyl group; R 3 is hydrogen, unbranches or branched alkyl with 1 to 10 carbon atoms, carboxyl or alkoxycarbonyl wherein the alkoxy contains from 1 to 4 carbon atoms; and R 4 is hydrogen, unbranched or branched alkyl with 1 to 4 carbon atoms; or acid addition or quaternary ammonium salts thereof.

Process for preparing telmisartan

The present invention refers to an improved process for the preparation of telmisartan or a pharmaceutical acceptable salt thereof through hydrolysis compounds of formula general I wherein R is selected from tert -butyl ester (Ia) or from nitrile (Ib) or salts thereof, using the same reaction conditions and reagents. Preferably, the invention discloses the preparation of telmisartan through hydrolysis of novel organic salts of compounds of formula I, particularly wherein R is tert -butyl ester (Ia). The invention also relates to a process for the preparation of these novel organic salts, in particular wherein R is tert -butyl ester(Ia) and its use in the preparation of telmisartan.

Novel alkylenebisbenzimidazoles and their preparation processes

Amorphous and polymorphic forms of telmisartan sodium

Provided is (Formula (I)) the amorphous form of telmisartan sodium and the preparation thereof. Also provided are the telmisartan sodium polymorph crystal Forms 0 to XIII and XV to XX and preparations thereof. Also provided are pharmaceutical composition of amorphous and polymorphic forms of telmisartan sodium or mixtures thereof, and methods of treatment of a mammal in need thereof.

2,5-BIS (2-BENZAZOLYL) HYDROQUINONES AND THEIR DERIVATIVES

A process for the preparation of telmisartan

The present invention encompasses a method for the preparation of Telmisartan comprises, through Telmisartan dihydrochloride comprises i) Condensing 4-Methyl-2-n-propyl-lH- benzimidazole-6-carboxylic acid with N-Methyl-O-phenylenediamine dihydrochloride to yields 4-methyl-6 (1 -methyl benzimidazol-2-yl)-2-n-propyl lH-benzimidazole ii) Treating 4- methyl-6-(l -methyl benzimidazol-2-yl)-2-n-propyl-lH-benzimidazole with 4`- (bromomethyl)-2-biphenyl-2-carboxylate in presence of a base in an organic solvent and isolating the ester as acid addition salt iii) Converting ester acid addition salt to Telmisartan dihydrochloride and iv) Converting Telmisartan dihydrochloride to Telmisartan.

An improved process for the preparation of substantially pure telmisartan

The present invention relates to an improved process for the preparation of substantially pure Telmisartan in polymorphic form A.